Record,Field,User,Datetime,Comment
1,ve_infant_vax_n,cdugdale.mgh.harvard.edu,"2025-07-25 20:26:57","Using this first set of fields for 90 day RSV-MA-LRTI"
1,ve_infant_vax_n_2,cdugdale.mgh.harvard.edu,"2025-07-25 20:30:57","These fields are for 180 day RSV-MA-LRTI"
1,ve_infant_vax_n_3,cdugdale.mgh.harvard.edu,"2025-07-25 20:33:30","These fields are for 90 day hospitalization"
1,ve_infant_vax_n_4,cdugdale.mgh.harvard.edu,"2025-07-25 20:35:03","These fields are for 180 day hospitalization"
1,ve_other_vax_n,cdugdale.mgh.harvard.edu,"2025-07-25 20:29:07","These fields are 240 day RSV-MA-LRTI"
1,ve_other_vax_n,cdugdale.mgh.harvard.edu,"2025-07-25 20:31:27",Updated
1,ve_other_vax_n_2,cdugdale.mgh.harvard.edu,"2025-07-25 20:32:26","These fields are for 360d RSV-MA-LRTI"
1,ve_other_vax_n_3,cdugdale.mgh.harvard.edu,"2025-07-25 20:34:16","These fields are for 360 day hospitalization"
5,domain,scottja.stanford.edu,"2025-07-27 21:53:21","Eric had checked AE and VE but I think the paper only covers VE."
10,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-07-26 15:25:07","propensity score"
10,ae_outcome1_em_type_2,emeyerowit.montefiore.org,"2025-07-26 15:23:25","Propensity score"
10,ae_outcome1_em_type_3,emeyerowit.montefiore.org,"2025-07-26 15:25:22","propensity score"
10,ae_outcome1_em_type_4,emeyerowit.montefiore.org,"2025-07-26 15:26:54","propensity score"
10,ae_outcome1_em_type_5,emeyerowit.montefiore.org,"2025-07-26 15:27:56","propensity score"
10,ae_outcome1_em_type_6,emeyerowit.montefiore.org,"2025-07-26 15:28:48","propensity score"
16,ae_incidence_yn,emeyerowit.montefiore.org,"2025-07-26 16:39:28","2 cases"
16,ae_incidence_yn_2,emeyerowit.montefiore.org,"2025-07-26 16:40:02","2 cases"
16,ae_incidence_yn_3,emeyerowit.montefiore.org,"2025-07-26 16:40:20","27 cases"
16,ae_incidence_yn_4,emeyerowit.montefiore.org,"2025-07-26 16:40:40","2 cases"
16,ae_incidence_yn_5,emeyerowit.montefiore.org,"2025-07-26 16:41:12","1 case"
16,ae_incidence_yn_6,emeyerowit.montefiore.org,"2025-07-26 16:41:34","1 case"
19,ae_outcome,scottja.stanford.edu,"2025-07-26 18:03:13","Outcome is Large for Gestational Age, but the preset list doesn't include LGA; no free‑text option available."
19,ae_outcome1_em_type,ncmccann.bu.edu,"2025-07-28 13:16:31","The odds ratio refers to comparison between COVID and flu- so not reported for flu vs. no vax."
19,ae_vax_type,ncmccann.bu.edu,"2025-07-28 13:42:53","Influenza vaccines, not specified"
19,domain_ae_include_vax,scottja.stanford.edu,"2025-07-27 20:32:27","unspecified influenza vaccine"
19,domain_ae_num,scottja.stanford.edu,"2025-07-27 20:36:46","The study compared events in the mRNA group to those who received influenza (comparator)."
19,domain_ae_num,ncmccann.bu.edu,"2025-07-28 12:43:54","Because mRNA is not disaggregated, I don't think we can use those results. But we can use the flu vax data"
19,virus,ncmccann.bu.edu,"2025-07-28 13:05:16","This paper collects COVID vax data, but we are excluding it because it does not disaggregate by product."
20,ae_incidence_yn,scottja.stanford.edu,"2025-08-05 01:22:59","This is a case-control study. Counts represent sampled cases and controls, not population-level incidence rates."
20,ae_incidence_yn_v2,scottja.stanford.edu,"2025-08-05 01:24:14","This is a case-control study. Counts represent sampled cases and controls, not population-level incidence rates"
22,ae_outcome1_em_type,scottja.stanford.edu,"2025-07-26 19:53:11","prevalence ratio"
22,ae_outcome1_em_value,ncmccann.bu.edu,"2025-07-28 14:01:43","Adjusted: 0.91, CI: 0.80-1.04"
22,ae_outcome1_em_value_v2,ncmccann.bu.edu,"2025-07-28 14:11:00","Adjusted: 0.88 (0.65 to 1.21)"
22,ae_outcome1_otherinfo_yn,scottja.stanford.edu,"2025-07-26 19:54:26","organ‑system sub‑analyses"
24,ae_outcome,emeyerowit.montefiore.org,"2025-07-26 20:40:53","Pregnancy loss - composite outcome including spontaneous miscarriage, death in utero, medical termination of pregnancy"
24,ae_outcome1_vax_n,emeyerowit.montefiore.org,"2025-07-26 20:39:20","82.2% of 938"
24,ae_outcome1_vax_n_v2,emeyerowit.montefiore.org,"2025-07-26 20:41:53","11.6% of 938"
25,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-07-26 20:53:52","Relative Odds Ratio"
25,domain_ae_include_yn,emeyerowit.montefiore.org,"2025-07-26 20:49:50","Note that the study also reports rates of myocarditis for influenza vaccines"
27,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-07-26 21:17:04","Odds ratio is for spina bifida - other odds ratios are available for some of the other defects"
27,ae_outcome1_vax_n,emeyerowit.montefiore.org,"2025-07-26 21:16:37","195+2033 = 2228 with defects. (4.1% vax = 91 defects)
1333 + 1360 = 2693 controls. (4.5% vax = 121 controls)"
30,ae_outcome1_otherinfo_yn,cdugdale.mgh.harvard.edu,"2025-07-26 20:29:02","Weighted HR: 0.83 (0.47-1.47)"
30,ae_outcome1_otherinfo_yn_2,cdugdale.mgh.harvard.edu,"2025-07-25 21:23:41","Weighted HR: 0.61 (0.50, 0.74)"
30,ae_outcome1_otherinfo_yn_3,cdugdale.mgh.harvard.edu,"2025-07-25 21:25:41","Weighted HR: 0.99 (0.76, 1.30)"
30,ae_outcome1_unvax_n,cdugdale.mgh.harvard.edu,"2025-07-26 20:28:02","Back calculated based on data in Table 2 on cumulative incidence and # events"
30,ae_outcome1_unvax_y_2,cdugdale.mgh.harvard.edu,"2025-07-25 21:23:02","Calculated from % in Table 2"
30,ae_outcome1_vax_n,cdugdale.mgh.harvard.edu,"2025-07-26 20:27:49","Back calculated based on data in Table 2 on cumulative incidence and # events"
30,ae_outcome1_vax_yes_2,cdugdale.mgh.harvard.edu,"2025-07-25 21:22:32","Calculated from % in table 2"
31,ae_outcome1_otherinfo_yn_2,cdugdale.mgh.harvard.edu,"2025-07-26 20:11:59","Weighted HR: 0.61 (0.50, 0.74)"
31,ae_outcome1_otherinfo_yn_3,cdugdale.mgh.harvard.edu,"2025-07-26 20:13:02","Weighted HR: 0.99 (0.76, 1.30)"
31,ae_outcome1_unvax_y_2,cdugdale.mgh.harvard.edu,"2025-07-26 20:11:32","Calculated from % in Table 2"
31,ae_outcome1_vax_yes_2,cdugdale.mgh.harvard.edu,"2025-07-26 20:11:12","Calculated from % in table 2"
32,ae_outcome1_em_type,scottja.stanford.edu,"2025-07-26 23:42:21","prevalence ratio"
32,domain_ae_num,scottja.stanford.edu,"2025-07-26 23:33:53","Study includes both BNT162b2 and mRNA‑1273, but primary safety analysis 
pools the two brands (no separate counts vs unvaccinated)."
33,ae_outcome1_em_type,scottja.stanford.edu,"2025-07-27 01:21:44","they compared to background rates"
33,ae_outcome1_em_value,scottja.stanford.edu,"2025-07-27 01:25:07","Registry prevalence of any major structural birth defect: 3.8 % (750/19 931 live births). Authors compare to pre-pandemic baseline;
no internal unvaccinated comparator; therefore no ratio entered."
33,ae_outcome1_otherinfo_yn,scottja.stanford.edu,"2025-07-27 01:26:05","Tthey stratified by < 14 vs >= 14 weeks vaccination"
33,domain_ae_num,scottja.stanford.edu,"2025-07-27 01:10:25","Pfizer‑BioNTech, Moderna, and Janssen - but products are pooled."
34,ae_incidence_yn,cdugdale.mgh.harvard.edu,"2025-07-25 21:06:08","Cannot calculate overall incidence from case-control design."
34,ae_incidence_yn_v2,cdugdale.mgh.harvard.edu,"2025-07-25 21:05:30","Cannot calculate overall incidence from a case-control study design."
34,ae_outcome,cdugdale.mgh.harvard.edu,"2025-07-25 20:54:47","Miscarriage/spontaneous abortion"
34,ae_outcome1_em_value,cdugdale.mgh.harvard.edu,"2025-07-25 21:01:46","Also has aOR: 0.97 (0.57-1.66)"
34,ae_outcome1_otherinfo_yn,cdugdale.mgh.harvard.edu,"2025-07-25 21:02:16","aOR 0.97 (0.57-1.66)"
34,ae_outcome1_otherinfo_yn_v2,cdugdale.mgh.harvard.edu,"2025-07-25 21:05:12","Crude OR: 0.69 (0.37-1.31)
aOR: 0.59 (0.29-1.19)"
34,date_end_month,cdugdale.mgh.harvard.edu,"2025-07-25 20:52:59","Exact month chosen based on spontaneous abortion dates rather than LMP"
35,ae_outcome1_disagg,scottja.stanford.edu,"2025-07-27 01:53:31","While the study disaggregates outcomes by age groups and also disaggregates by vaccine type (Pfizer/mRNA vs. AstraZeneca/viral-vector), it does not explicitly provide a table or specific numerical results for the Pfizer (BNT162b2) vaccine's outcomes further disaggregated by age group in the main text or figures."
35,ae_outcome1_otherinfo_yn,scottja.stanford.edu,"2025-07-27 01:51:44","The study further classified preterm birth into ""extremely and very preterm (24-31 wks)"" and ""moderate to late preterm (32-36 wks)"
35,domain_ae_num,scottja.stanford.edu,"2025-07-27 01:39:33","The study included data on ChAdOx1-S and BNT162b2; since we're not reviewing ChAdOx1-S data, I selected ""1"" product to only extract data for the BNT162b2 vaccine."
38,ve_outcome_prime,stodd046,"2025-07-28 18:13:33","Should this be medically-attended infection instead of other?"
38,ve_overall_em,harleen.k.marwah.gmail.com,"2025-07-26 23:09:51","The cumulative incidence of RSV infections from swabs collected due to suspected LRTI was lower with nirsevimab versus placebo at day 151 (Δ −5.6; Figure 1A); this difference increased slightly at day 361 (Δ −5.9) and day 511 (Δ −6.4)."
39,ae_outcome1_vax_y,emeyerowit.montefiore.org,"2025-08-04 21:35:23","Note 1 ""cardiac disorder"" noted in part 2 group in supplement, but they say 0 cases of myocarditis identified in the study overall so must have been deemed to not be myocarditis"
39,ae_vax_type,emeyerowit.montefiore.org,"2025-08-04 21:34:41","technically mRNA-1273.214 vaccine which was for BA1 variant"
39,domain_ae_include_vax,harleen.k.marwah.gmail.com,"2025-07-26 23:45:17",mRNA-1273.214
44,ve_maternalvax,emeyerowit.montefiore.org,"2025-07-27 08:30:02","Ended Feb 2023, likely before maternal RSV vaccination available"
49,ve_comparator1,emeyerowit.montefiore.org,"2025-07-27 09:10:40","6.6% of all in pre-N seasons received palivizumab (vast majority unimmunized)"
49,ve_overall_unvax_n,emeyerowit.montefiore.org,"2025-07-27 09:21:02","377 RSV PICU admissions pre N * 100/9 = 4189 total PICU admissions"
49,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-07-27 09:20:22","31 RSV PICU admissions post N *100/4.3 = 721 total admissions"
50,epi_ifr_covid,emeyerowit.montefiore.org,"2025-07-27 09:28:13","In hospital mortality"
50,epi_ifr_flu,emeyerowit.montefiore.org,"2025-07-27 09:30:32","In hospital mortality"
50,epi_ifr_rsv,emeyerowit.montefiore.org,"2025-07-27 09:29:40","in hospital mortality"
51,ve_overall_em,emeyerowit.montefiore.org,"2025-07-27 09:40:33","Also has VE of 82.0%, 95% CI 655.6-90.2%"
52,ve_infant_em,emeyerowit.montefiore.org,"2025-07-27 09:55:14","Data is disaggregated by follow up month (time since N immunization) not by age group of interest in Table 3"
55,date_start_month,harleen.k.marwah.gmail.com,"2025-08-12 10:40:28","out of date range"
55,epi_hospitalization_rsv,emeyerowit.montefiore.org,"2025-07-27 17:30:15","Of total cohort"
59,domain,harleen.k.marwah.gmail.com,"2025-08-01 10:07:50","""Safety and infectious outcomes in pediatric kidney transplant  recipients"" - Described as safety, though also looks at VE for this population (not within our VE date window, however)"
59,population_disagg,harleen.k.marwah.gmail.com,"2025-08-01 10:10:14","Per patient"
62,ve_outcome_prime_other,emeyerowit.montefiore.org,"2025-07-27 20:09:34","Bronchitis episodes as reported in follow-up parental questionnaire regarding the last 12 months before 5-6-year follow-up examination."
62,ve_overall_vax_y,emeyerowit.montefiore.org,"2025-07-27 20:08:45","Calculated from data on page 12, section 3.5"
73,ae_outcome1_vax_y,ncmccann.bu.edu,"2025-07-27 21:43:34","this is less than 6"
79,ve_infant_em_adj,calba1.mgh.harvard.edu,"2025-07-29 20:40:51","(adjusted VE 95%CI: 34.1-67.3)"
81,population_premature,emeyerowit.montefiore.org,"2025-07-28 15:21:50","Among the 1286 children included aged < 2 years"
81,ve_infant_em_adj,emeyerowit.montefiore.org,"2025-07-28 15:29:48","CI 79-94"
81,ve_infant_em_ci,emeyerowit.montefiore.org,"2025-07-28 15:29:34",unadjusted
81,ve_infant_vax_n,emeyerowit.montefiore.org,"2025-07-28 15:28:47","supplementary table eTable 8"
81,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-07-28 15:31:53","CI 79-94"
81,ve_overall_em_adj_2,emeyerowit.montefiore.org,"2025-07-28 15:32:38","CI 82-97"
81,ve_overall_em_ci,emeyerowit.montefiore.org,"2025-07-28 15:31:44",unadjusted
81,ve_overall_em_ci_2,emeyerowit.montefiore.org,"2025-07-28 15:32:29",unadjusted
81,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-07-28 15:32:54","Data in supplementary table eTable 8"
82,domain_ae_include_list,harleen.k.marwah.gmail.com,"2025-07-29 18:47:23","4 common post-vaccination symptom categories such as local, general, musculoskeletal symptoms and fever"
83,population_premature,harleen.k.marwah.gmail.com,"2025-07-28 16:40:31","Calculated from Table 1A"
83,population_premature,ncmccann.bu.edu,"2025-07-29 20:25:51","Confirmed calculation"
83,ve_em_type,ncmccann.bu.edu,"2025-07-30 07:49:37","They don't explicitly state their definition, it seems most likely 1-OR * 100 since they used logistic regression (which typically produces odds ratios unless otherwise specified), but since they don't state it, leave as ""other."""
83,ve_overall_em,harleen.k.marwah.gmail.com,"2025-07-28 16:51:26","Pragmatic estimates of effectiveness (95% CI) were obtained from conditional logistic models based on the actual immunisation status at  the matching date and adjusting for sex, gestational age, birth weight, multiple pregnancy, previous non-RSV hospitalisation, and previous  comorbidities up to that date. Analyses were based on cases and controls with complete covariate information"
83,ve_overall_em,ncmccann.bu.edu,"2025-07-30 07:47:52","Given that they used a logistic regression I would guess this is adjusted, (1-OR)*100, but they don't explicitly state that, so leaving as ""other""."
83,ve_overall_vax_n,harleen.k.marwah.gmail.com,"2025-07-28 16:50:43","Calculated looking at table 2"
85,rob_screen2,stodd046,"2025-08-28 16:05:50","The primary outcome of the paper was nirsimivab acceptance (for which they controlled for confounders with MV regression) but that is outside of our scope. The primary outcome I'm assessing is AEs for which I did not see strong evidence of confounder control."
86,ve_overall_em,harleen.k.marwah.gmail.com,"2025-07-28 17:32:48","for at birth immunization"
86,ve_overall_vax_n,harleen.k.marwah.gmail.com,"2025-07-28 17:29:47","# of hospitalized RSV cases"
86,ve_overall_vax_y,harleen.k.marwah.gmail.com,"2025-07-28 17:30:14","# vaccinated (calculated from %'s in Table)"
87,epi_sample_rsv,emeyerowit.montefiore.org,"2025-07-29 06:34:28","Total RSV hospitalizations during study period"
88,ve_infant_unvax_y,ncmccann.bu.edu,"2025-07-30 09:14:37","Conversely, in the control group, we observed 10 hospital emer-
gency visits, 34 hospital admissions and 14 ICU admissions"
88,ve_infant_vax_y,ncmccann.bu.edu,"2025-07-30 09:14:11","""Among infants immunized with nirsevimab, there were 56 
hospital emergency visits for RSV-associated bronchiolitis, 109 
hospital admissions and 25 ICU admissions"
89,date_start_month,emeyerowit.montefiore.org,"2025-07-29 06:53:59","Non-continuous study period."
89,ve_child_vax_n,ncmccann.bu.edu,"2025-07-30 09:32:53","summed the 2 older age groups"
92,population,ncmccann.bu.edu,"2025-07-30 12:00:29","< 21 years"
94,ve_child_em_adj,emeyerowit.montefiore.org,"2025-07-29 14:46:12","Adjusted for sex, age at the start of each influenza season, Italian region of birth, deprivation index, comorbidities, and influenza vaccination status, number of influenza/ILI episodes, antibiotic therapies, and primary care visits in the preceding season of interest"
94,ve_child_em_adj_v2,emeyerowit.montefiore.org,"2025-07-29 14:48:47","adjusted in same way as before"
94,ve_child_em_ci,emeyerowit.montefiore.org,"2025-07-29 14:45:10",adjusted
94,ve_child_em_ci_v2,emeyerowit.montefiore.org,"2025-07-29 14:48:51",adjusted
95,population,emeyerowit.montefiore.org,"2025-07-30 08:59:41","Note according to Table 6, 28/32 are < 6 months"
95,ve_infant_vax_n,emeyerowit.montefiore.org,"2025-07-30 09:05:03","Table 6 - total number cases < 6 months"
95,ve_maternalvax,emeyerowit.montefiore.org,"2025-07-30 08:45:49","Note from page 2: "" It is important to note that a maternal immunisation programme against RSV had not yet been implemented in Spain at the time of this study"""
95,ve_overall_unvax_n,emeyerowit.montefiore.org,"2025-07-30 09:04:25","Table 6 - total controls"
95,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-07-30 08:57:36","Table 6 - total number cases"
99,ve_vax_type,emeyerowit.montefiore.org,"2025-07-30 09:22:05","Note 16 received LAIV, but were excluded from analysis"
100,rob_screen2,flemi644,"2025-08-28 11:48:50","myocarditis/pericarditis was handled descriptively, not with adjusted comparative modeling"
101,nos_cc_5,flemi644,"2025-08-28 12:39:18","Adjusted models; key confounders include age and comorbidity burden.

Sex, race/ethnicity, BMI, prior documented infection, health-care utilization, influenza vaccination, etc"
101,rob_screen2,flemi644,"2025-08-28 12:44:14","prior infection only captured when documented"
101,ve_child_vax_n,emeyerowit.montefiore.org,"2025-07-30 10:46:55","Use supplementary figure 1 for next sections"
101,ve_overall_vax_n_2,emeyerowit.montefiore.org,"2025-07-30 10:37:24","Includes hospitalization and ED/urgent care visits"
101,ve_overall_vax_n_2_v2_v3,emeyerowit.montefiore.org,"2025-07-30 10:46:30","Calculated from supplementary Figure 1"
101,ve_vax_type,emeyerowit.montefiore.org,"2025-07-30 10:39:35","For ages 5-11"
102,author,emeyerowit.montefiore.org,"2025-07-30 11:35:48","Note - article in COVIDENCE is wrong. Need to pull it up either in Zotero or online from CID"
102,ve_adult_vax_n_3,emeyerowit.montefiore.org,"2025-07-30 11:33:56","Note this is for ages >/= to 18. Not disaggregated by age >65"
103,ae_incidence_yn,harleen.k.marwah.gmail.com,"2025-07-28 17:45:49","Provides information on number of myocarditis cases w/ COVID vaccine but not otherwise in the population. ""Among 168 confirmed cases, 73 (43%) were COVID-19 mRNA vaccine-proximate cases, 47 (28%) were remotely vaccinated, 39 (23%) were unvaccinated, and 9 (5%) had unknown vaccination status"""
103,ae_vax_type,harleen.k.marwah.gmail.com,"2025-07-28 17:43:57","""mRNA COVID vaccines"""
104,date_start_month,emeyerowit.montefiore.org,"2025-07-29 15:55:51","Included RSV seasons 2019, 2022, and 2024 (non-continuous study period)"
104,ve_outcome_prime_txt,emeyerowit.montefiore.org,"2025-07-29 16:07:38","In Supplementary Table 5"
104,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-07-29 16:13:48","""The effectiveness of nirsevimab was estimated using the stratified Cox proportional hazards model with time-variant covariates, including age, sex, wga, region and rurality in the stratification"""
105,date_end_month,emeyerowit.montefiore.org,"2025-07-30 12:59:26","day 56"
106,domain,harleen.k.marwah.gmail.com,"2025-08-01 09:41:11","VE on long COVID"
106,ve_em_type,harleen.k.marwah.gmail.com,"2025-08-01 09:44:28","effectiveness was reported as (1-relative risk)*100 and mediating effects were reported as relative risks"
106,ve_overall_em,harleen.k.marwah.gmail.com,"2025-08-01 09:48:53","During the Delta variant phase, the BNT162b2 vaccine exhibited an estimated overall vaccine effectiveness against long COVID of 95.4% (95% CI: 90.9%-97.7%) among adolescents."
106,ve_overall_em_2,harleen.k.marwah.gmail.com,"2025-08-01 09:50:02","During the Omicron phase, the estimated overall vaccine effectiveness against long COVID was 60.2% (95% CI: 40.3%-73.5%) for children"
106,ve_overall_em_3,harleen.k.marwah.gmail.com,"2025-08-01 09:50:56","For adolescents, it was 75.1% (95% CI: 50.4%-87.5%)"
106,ve_overall_vax_n_2,harleen.k.marwah.gmail.com,"2025-08-01 09:53:10","Table 2"
106,ve_overall_vax_n_3,harleen.k.marwah.gmail.com,"2025-08-01 09:53:04","Table 2"
106,ve_vax_type,harleen.k.marwah.gmail.com,"2025-08-01 09:43:30","VE on long COVID"
107,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-08-27 19:22:30","AdjustedORestimatedusinglogisticregressionwithunvaccinatedasreferentgroupadjustedforsex,ageatinfection,numberofsymptomsexperiencedduringinfection,self-rated
 health at baseline, and time betweeninfection andsurveycompletion."
107,ve_overall_em_ci,emeyerowit.montefiore.org,"2025-08-27 19:22:37","adjusted CI"
109,ae_outcome1_vax_n,harleen.k.marwah.gmail.com,"2025-07-29 12:33:36","# of doses (not # of vaccinated)"
112,ae_incidence_yn,harleen.k.marwah.gmail.com,"2025-07-29 17:57:23","one case of nonserious, moderate, probable acute myocarditis resolved by 8 days from symptom onset"
112,ae_outcome,harleen.k.marwah.gmail.com,"2025-07-29 17:58:05","An independent cardiac event adjudication committee (CEAC) reviewed suspected cases of myocarditis and pericarditis to determine if they met Centers for Disease Control and Prevention (CDC) criteria of ""probable"" or ""confirmed"" events"
112,ae_outcome1_longterm_yn,harleen.k.marwah.gmail.com,"2025-07-29 17:58:35","One AE of chest pain was adjudicated as probable myocarditis; this event was mild and self-limited, with no evidence of sequelae, which is consistent with most cases of myocarditis postvaccination."
113,domain_ae_include_yn,harleen.k.marwah.gmail.com,"2025-07-29 15:10:07","The study has a category called ""Adverse events of special interest."" In the supplementary materials (available online), Appendix 4/Table 17/page 192 lists out the AESIs and includes Guillain-Barre Syndrome on the list. However, there is no disaggregation of AESIs so cannot draw any conclusions about the specific AEs listed."
114,domain_ae_include_vax,harleen.k.marwah.gmail.com,"2025-07-29 13:16:13","booster dose"
116,ae_vax_type,harleen.k.marwah.gmail.com,"2025-07-28 13:49:45","About Pfizer BA.1 or BA.4/5 vaccine"
121,ve_infant_em,harleen.k.marwah.gmail.com,"2025-07-29 14:44:46","Among infants under 3 months of age, hospitalizations decreased by 79.3% (IRR: 0.21, 95% CI: 0.12-0.34). In infants aged 3 to 6 months, there was a 66.9% reduction (IRR: 0.33, 95% CI: 0.15-0.64)."
121,ve_infant_em,harleen.k.marwah.gmail.com,"2025-07-29 14:45:05","Reported by 0-3 mo and 3-6 mo"
121,ve_infant_em_2,harleen.k.marwah.gmail.com,"2025-07-29 14:49:00","Reported as < 3 months and 3-6 months (Table 3)"
124,coadmin_pop1_n,emeyerowit.montefiore.org,"2025-07-30 13:27:00","Fig 1 - only those who received BNT162b2"
129,date_explain,harleen.k.marwah.gmail.com,"2025-08-04 12:10:26","Interim safety and immunogenicity 29 days after vaccination are reported."
129,date_explain,harleen.k.marwah.gmail.com,"2025-08-04 12:10:50","Interim 15- and 29-day analysis results are reported."
129,date_start_month,harleen.k.marwah.gmail.com,"2025-08-04 12:12:08","April 2023"
129,domain_ae_inc_other,harleen.k.marwah.gmail.com,"2025-08-04 12:12:51","local and systemic reactions (Figure 2)"
129,setting,harleen.k.marwah.gmail.com,"2025-08-04 12:11:08","The trial is being conducted across 9 US sites"
131,coadmin_pop1_n,emeyerowit.montefiore.org,"2025-07-31 06:35:48","Only study part B was co-admin"
132,coadmin_sero_other,emeyerowit.montefiore.org,"2025-07-31 06:51:42","Unclear clinical significance"
132,coadmin_sero_other,emeyerowit.montefiore.org,"2025-07-31 07:01:00","Second trial with this finding"
133,design,abersm.gmail.com,"2025-07-30 14:00:19","Secondary analysis of previously reported RCT"
135,coadmin_ae_yn,emeyerowit.montefiore.org,"2025-07-31 07:12:08","Relative risk of AEs (reactogenicity) not significantly different comparing coadmin to COVID booster only group."
138,ae_outcome,emeyerowit.montefiore.org,"2025-07-31 08:57:39","1 case of myocarditis in the mRNA-1273 group reported, see Table S16 in supplementary material"
138,ae_outcome1_vax_n,scottja.stanford.edu,"2025-08-08 02:53:10","I changed that it does provide incidence data and added 1 out of 374 with myocarditis. P10, table 3"
138,domain_ae_num,scottja.stanford.edu,"2025-08-08 02:45:35","I changed this from 1 to 3"
138,population_disagg,scottja.stanford.edu,"2025-08-08 02:42:43","Figure 2F  shows neutralizing antibody titers by disease cohort. The logistic regression analyses  identify factors (including age, disease cohort, and treatments) contributing to the likelihood of immune responses. Serious adverse events are split by treatment group and disease group in the appendix"
141,domain_ae_include_vax,harleen.k.marwah.gmail.com,"2025-08-02 15:41:16","Ad26/protein preF RSV"
141,population_disagg,harleen.k.marwah.gmail.com,"2025-08-02 15:43:34","Disaggregated by further age groups (18-45, 46-59, 65-74, 75-84, 85+)"
143,ve_overall_em_adj,ncmccann.bu.edu,"2025-08-03 11:18:14","Note that this is the VE for what we are specifying as the comparator."
145,date_start_month,harleen.k.marwah.gmail.com,"2025-08-04 13:47:51","in supplementary materials"
147,design,ncmccann.bu.edu,"2025-08-11 12:25:15","participants randomized, but not really described as a trial"
156,domain_ae_include_yn,ncmccann.bu.edu,"2025-08-05 20:46:40","USED CLINICALTRIALS.GOV TO GET SPECIFIC AES. There were serious AEs reported, but not stated which kind in the publication, so went to the clinical trial website. https://clinicaltrials.gov/study/NCT05827978?tab=results#adverse-events"
158,domain_ae_include_vax,harleen.k.marwah.gmail.com,"2025-08-02 16:02:39","Ad26.RSV.preF/RSV preF protein vaccine"
159,coadmin_pop1_n,emeyerowit.montefiore.org,"2025-08-03 16:02:26","Not disaggregated by mRNA vaccine brand"
165,ae_incidence_yn,emeyerowit.montefiore.org,"2025-08-03 16:21:48","The study included a cohort of individuals with preexisting ITP."
167,ae_outcome,abersm.gmail.com,"2025-07-29 20:29:58","Data are for ischemic stroke"
167,ae_outcome1_otherinfo_yn,stodd046,"2025-08-06 11:27:33","This study reports IRR for ""cerebro-vascular"" events which includes stroke but does not disaggregate"
167,design,stodd046,"2025-08-06 10:51:37","I switched this designation from ""Other"" to ""Observational"" based on 8/5 meeting discussion"
169,ve_outcome_prime_txt,emeyerowit.montefiore.org,"2025-08-05 20:00:32","Supplementary eTable3"
169,ve_timeline,emeyerowit.montefiore.org,"2025-08-05 20:04:53","Model 4 is in table 2"
170,ve_outcome_prime,emeyerowit.montefiore.org,"2025-08-05 20:31:17","Table 2"
170,ve_overall_vax_n_2,emeyerowit.montefiore.org,"2025-08-05 20:32:37","Table 1"
173,date_start_year,stodd046,"2025-08-06 11:42:52","""from the inception of the VAERS"""
178,domain_ae_include_list,abersm.gmail.com,"2025-07-31 17:11:20","Other heme parameters not disaggregated by vaccine"
181,virus,abersm.gmail.com,"2025-07-31 17:05:28","No disaggregation by specific COVID vaccine. No disaggregation by specific influenza vaccine"
182,immunocomp_describe,harleen.k.marwah.gmail.com,"2025-08-04 13:52:29","1) solid organ transplant recipients (including heart, lung, liver, or
kidney) who received their transplant at least 3 months before enrollment and with no
acute rejection episodes within the previous 2 months; (2) individuals receiving active
immunomodulator therapy for an autoimmune inflammatory disorder at a stable dose
(i.e., receiving the same dose for at least 3 months with no changes in the 28 days before
enrollment); (3) individuals with advanced non-small cell lung cancer who received initial
or maintenance chemotherapy for at least 2 weeks before enrollment, individuals who are
treatment-naive and not expected to receive chemotherapy within at least 2 weeks after
study vaccinations, or those who received checkpoint inhibitor treatment or targeted drug
therapy (i.e., tyrosine kinase inhibitors, including epidermal growth factor receptor [EGFR],
anaplastic lymphoma kinase [ALK], c-ros oncogene 1 [ROS1], v-raf murine sarcoma viral
oncogene homolog B1 [BRAF], rearranged during transfection [RET], and neurotrophic
tyrosine receptor kinase [NTRK] inhibitors) for at least one treatment cycle before enroll-
ment; and (4) individuals on maintenance hemodialysis treatment secondary to end-stage
renal disease."
184,ae_vax_type,stodd046,"2025-08-08 11:33:52","Evaluating NVX-CoV2601"
185,ae_vax_type,stodd046,"2025-08-08 11:50:00",NVX-CoV2601
188,domain_ae_include_vax,stodd046,"2025-08-11 10:43:27","mRNA-1273.214 or BA.1-adapted BNT162b2"
189,ve_adult_vax_n,stodd046,"2025-08-08 12:01:37","Please see note in general info- authors include this population but report VE in a strange way. 18 and over is reported in this form as ""Overall Population"""
205,ve_overall_vax_n,harleen.k.marwah.gmail.com,"2025-08-04 16:41:42","Table #3 has this listed by events/person-years"
206,date_start_year,harleen.k.marwah.gmail.com,"2025-08-04 17:37:26","They also had a cohort from 22-23 season, but just looking at the 23-24 season for this extraction"
206,epi_other_covid,harleen.k.marwah.gmail.com,"2025-08-04 17:39:05","During the 2023 to 2024 season, the 30-day risk of hospitalization was similar for COVID-19 (16.2%) and influenza (16.3%) but lower for RSV at 14.3% (RD for COVID-19 vs RSV, 1.9% [95% CI, 0.9%-2.9%]; RD for influenza vs RSV, 2.0% [95% CI, 0.8%-3.3%]). The 30-day risk of death during the 2022 to 2023 season was slightly higher for COVID-19 (1.0%) compared with influenza (0.7%) (RD, 0.4% [95% CI, 0.1%-0.6%]) or RSV (0.7%) (RD, 0.4% [95% CI, 0.1%-0.6%]) but similar during the 2023 to 2024 season. Mortality risk at 180 days was higher for COVID-19 during both seasons (2023-2024 RD for COVID-19 vs influenza, 0.8% [95% CI, 0.3%-1.2%]; RD for COVID-19 vs RSV, 0.6% [95% CI, 0.1%-1.1%])."
210,ae_outcome1_vax_n,emeyerowit.montefiore.org,"2025-08-10 12:30:45","sum IC + matched groups"
211,population,abersm.gmail.com,"2025-07-31 17:21:00","Immunocompromised not specifically mentioned as inclusion criteria but study includes patients on chemo, XRT, target/endocrine therapy"
213,coadmin_ae_yn,harleen.k.marwah.gmail.com,"2025-08-01 10:38:16","Not reported"
213,coadmin_vax_num,harleen.k.marwah.gmail.com,"2025-08-01 10:36:48","Patients were managed as outpatients and simultaneously intramuscularly vaccinated against influenza (Vaxigrip Tetra, season 2023/ 2024, Sanofi, pre-filled syringe, batch number: X3E895V) (right arm) and RSV (Arexvy, GSK, batch number: 3X5K3) (left arm) from the 15th of September 2023 to the 17th of November 2023."
213,population,harleen.k.marwah.gmail.com,"2025-08-01 10:36:05","High Risk Heart Failure"
214,design,abersm.gmail.com,"2025-07-29 21:19:08","Propensity matched"
214,domain_ae_include_vax,harleen.k.marwah.gmail.com,"2025-08-04 18:05:59","Likely RSVpreF3 and RSVpreF given that is what is mentioned in the introduction"
214,population,abersm.gmail.com,"2025-07-29 21:19:17","Age >= 60"
214,setting,harleen.k.marwah.gmail.com,"2025-08-04 18:04:03","look at records of 108 million patients from 66 healthcare organizations, representing 27% of the US population from all 50 states"
215,ae_outcome1_otherinfo_yn,emeyerowit.montefiore.org,"2025-08-10 12:48:34","Has details about clinical presentation"
216,ve_elder_unvax_n,abersm.gmail.com,"2025-07-29 22:07:44","Calculated from Table 3"
216,ve_elder_unvax_y,abersm.gmail.com,"2025-07-29 22:07:51","Calculated from Table 3"
216,ve_elder_vax_n,abersm.gmail.com,"2025-07-29 22:07:31","Calculated from Table 3"
216,ve_elder_vax_y,abersm.gmail.com,"2025-07-29 22:07:39","Calculated from Table 2"
216,ve_em_type,abersm.gmail.com,"2025-07-29 22:15:01","Article states OR is used but after calculating their raw data, it's clear that (1-OR)*100 was used"
216,ve_other_unvax_n,abersm.gmail.com,"2025-07-30 16:31:51","Age 0-64"
216,ve_other_unvax_n_2,abersm.gmail.com,"2025-07-30 16:39:38","Age 0-64"
216,ve_other_unvax_y,abersm.gmail.com,"2025-07-30 16:31:55","Age 0-64"
216,ve_other_unvax_y_2,abersm.gmail.com,"2025-07-30 16:39:43","Age 0-64"
216,ve_other_vax_n,abersm.gmail.com,"2025-07-30 16:31:33","Age 0-64"
216,ve_other_vax_n_2,abersm.gmail.com,"2025-07-30 16:39:28","Age 0-64"
216,ve_other_vax_y,abersm.gmail.com,"2025-07-30 16:31:46","Age 0-64"
216,ve_other_vax_y_2,abersm.gmail.com,"2025-07-30 16:39:33","Age 0-64"
219,domain_ae_include_vax,moat0011,"2025-08-06 17:23:47","Vaccine products not specified"
220,epi_sample_rsv,harleen.k.marwah.gmail.com,"2025-08-04 18:21:54","27 withdrew during season 1, 77 between seasons 1 and 2, and 129 during season 2 and were censored at the time of withdrawal"
222,domain_ae_include_vax,stodd046,"2025-08-11 12:31:42","In our analysis, the cases were the AEFI reports for
which mRNA COVID-19 vaccines elasomeran-Spikevax® (Moderna) and tozinameran-Comirnaty® (Pfzer
& BioNTech), were suspected, while non-cases were AEFI
reports for which all other vaccines listed in Supplementary Table 1 (excluding non-mRNA COVID-19 vaccines)
were suspected"
223,domain,stodd046,"2025-08-11 13:01:41","EXCLUDE STUDY: SWITCHING TO VE SINCE THERE ARE NO AEs"
228,ve_comparator_vax_v2,flemi644,"2025-08-07 16:42:08","All non-xbb vaccinated + unvaccinated: listed as ""non-xbb vaccinated"" in table 2, with overall case and control totals matching table 1"
235,population_disagg,abersm.gmail.com,"2025-07-31 09:46:56","Age data not disaggregated by specific vaccine."
236,ve_overall_em_ci_2,emeyerowit.montefiore.org,"2025-08-10 07:31:20",adjusted
238,population_disagg,abersm.gmail.com,"2025-07-30 17:14:46","Individual patient data provided"
239,ae_incidence_yn,emeyerowit.montefiore.org,"2025-08-10 09:03:24","There were too few myocarditis events to disaggregate - listed as < 5 for multiple vaccines."
239,ae_incidence_yn,stodd046,"2025-08-12 10:41:53","After third dose of vaccine (multiple brands aggregated)"
239,ae_incidence_yn_2,emeyerowit.montefiore.org,"2025-08-10 09:04:03","Too few GBS events"
239,ae_outcome_v2,emeyerowit.montefiore.org,"2025-08-10 09:13:16","""any stroke + TIA"""
239,ae_outcome1_vax_n_3,emeyerowit.montefiore.org,"2025-08-10 09:11:25","Sum of 239030 + 232,765 + 414,077 for total BNT162b2 doses given for doses 1,2,3, from Table 1"
239,ae_outcome1_vax_n_4,emeyerowit.montefiore.org,"2025-08-10 09:10:53","Sum of 239030 + 232,765 + 414,077 for total BNT162b2 doses given for doses 1,2,3"
239,ae_outcome1_vax_n_v2,emeyerowit.montefiore.org,"2025-08-10 09:14:13","Number of 3rd dose mRNA-1273 vaccines"
239,ae_outcome1_vax_y_3,emeyerowit.montefiore.org,"2025-08-10 09:06:17","Sum of 48 + 41 + 37 for all events across all 3 doses of BNT162b2"
239,ae_outcome1_vax_y_3,stodd046,"2025-08-12 10:50:33","This information is found in supplementary figures S12-S14"
239,ae_outcome1_vax_y_4,emeyerowit.montefiore.org,"2025-08-10 09:05:39","Sum of 159 + 179  + 235 for all events across all 3 doses of BNT162b2"
239,domain,stodd046,"2025-08-12 10:32:29","Also has VE but out of date range"
244,domain_ae_include_vax,moat0011,"2025-08-12 13:54:14","Also included AZ, SInovac, and SInopharm"
245,domain_ae_include_vax,abersm.gmail.com,"2025-07-30 14:25:47","Article did not explicitly state influenza vaccine product. They only said that IIV is provided free of charge in Korea"
246,virus,scottja.stanford.edu,"2025-08-13 23:20:21","COVID vaccines are included too but not disaggregated."
249,ae_incidence_yn,flemi644,"2025-08-08 11:14:46","Number of administered doses"
249,ae_outcome_2,flemi644,"2025-08-08 12:28:00","""acute cardiovascular injury"" = ""myocarditis, pericarditis, and others;"" not disaggregated by vaccine brand"
249,ae_outcome_2_v2,flemi644,"2025-08-08 12:30:14","""acute cardiovascular injury"" = ""myocarditis, pericarditis, and others;"" not disaggregated by vaccine brand"
253,ve_adult_vax_n_3,emeyerowit.montefiore.org,"2025-08-10 13:50:02","Note: age 18-49"
253,ve_adult_vax_n_4,emeyerowit.montefiore.org,"2025-08-10 13:55:12","18-49 years"
253,ve_child_vax_n,emeyerowit.montefiore.org,"2025-08-10 13:53:22","8 months-17 years"
253,ve_child_vax_n_2,emeyerowit.montefiore.org,"2025-08-10 13:53:10","8 months - 17 years"
253,ve_child_vax_n_3,emeyerowit.montefiore.org,"2025-08-10 13:52:00","8 months-17 years"
253,ve_child_vax_n_4,emeyerowit.montefiore.org,"2025-08-10 13:57:07","8 months to 17 years"
253,ve_elder_vax_n_3,emeyerowit.montefiore.org,"2025-08-10 13:49:07","Note this is for >50"
253,ve_elder_vax_n_4,emeyerowit.montefiore.org,"2025-08-10 13:54:34",">50 years"
254,ae_incidence_yn,flemi644,"2025-08-08 13:04:47","Incidence is per-dose rates per 100,000 doses"
254,ae_outcome1_vax_n,flemi644,"2025-08-08 13:05:00",doses
254,ae_outcome1_vax_n_2,flemi644,"2025-08-08 13:08:50",doses
254,ae_outcome1_vax_y,flemi644,"2025-08-08 13:08:11","Myocarditis vs Pericarditis differentiated in the text (page 6). Myo + peri = 25"
254,ae_outcome1_vax_yes_2,flemi644,"2025-08-08 13:09:28","Specified in the text."
255,ve_adult_vax_n,emeyerowit.montefiore.org,"2025-08-10 14:07:14","age 15-64"
255,ve_child_em_ci,emeyerowit.montefiore.org,"2025-08-10 14:07:02","adjusted CI"
255,ve_child_vax_n,emeyerowit.montefiore.org,"2025-08-10 14:05:16","7 months to 14 years"
255,ve_overall_em_ci,emeyerowit.montefiore.org,"2025-08-10 14:10:37","adjusted CI"
261,date_start_month,abersm.gmail.com,"2025-08-04 13:11:12","Specific time period not mentioned. Authors state, ""March 2023, at the time this study was 
conducted"" in first line of discussion section."
265,ve_overall_em_ci,emeyerowit.montefiore.org,"2025-08-10 14:24:53","adjusted CI"
269,title,emeyerowit.montefiore.org,"2025-08-10 14:31:48","Vaccine in study: SK's Inactivated Quadrivalent Seasonal 
Influenza Vaccine (Fluarix Tetra)"
271,date_end_month,abersm.gmail.com,"2025-08-02 09:36:48","Last vaccination 7/2023"
274,domain_ae_include_vax,abersm.gmail.com,"2025-08-02 09:49:39","98% of vaccinations were Pfizer"
275,population,abersm.gmail.com,"2025-08-02 09:54:43","Age criteria not explicitly stated."
275,population_disagg,abersm.gmail.com,"2025-08-02 09:55:26","Age not disaggregated for each type of vaccine"
276,ve_comparator1,abersm.gmail.com,"2025-08-02 10:07:14","Note that P values in table 2 compare VE to standard dose QIV. However, VE calculated by comparing to unvaccinated."
276,ve_overall_vax_n,abersm.gmail.com,"2025-08-02 10:18:05","Data from table 2"
276,ve_overall_vax_n_2,abersm.gmail.com,"2025-08-02 10:18:29","Data from table 2"
276,ve_overall_vax_n_2_v2,abersm.gmail.com,"2025-08-02 10:25:54","Data from table 2"
276,ve_overall_vax_n_2_v2_v3,abersm.gmail.com,"2025-08-02 10:30:16","Data from table 2"
276,ve_overall_vax_n_3,abersm.gmail.com,"2025-08-02 10:18:35","Data from table 2"
276,ve_overall_vax_n_3_v2,abersm.gmail.com,"2025-08-02 10:25:48","Data from table 2"
276,ve_overall_vax_n_3_v2_v3,abersm.gmail.com,"2025-08-02 10:30:21","Data from table 2"
276,ve_overall_vax_n_v2,abersm.gmail.com,"2025-08-02 10:26:00","Data from table 2"
276,ve_overall_vax_n_v2_v3,abersm.gmail.com,"2025-08-02 10:30:10","Data from table 2"
276,ve_vax_type_v2_v3,abersm.gmail.com,"2025-08-02 10:28:04","QIV (Influvac Tetra or Vaxigrip Tetra). Standard dose."
276,ve_vax1_other_v2,abersm.gmail.com,"2025-08-02 10:22:30","All patients were age >= 70"
278,population,abersm.gmail.com,"2025-08-03 16:23:06","NOTE: Age ranges in study do not match definitions here exactly. See next form for details"
278,ve_adult_vax_n,abersm.gmail.com,"2025-08-03 16:38:57","Actual age range in study: 18-59 years"
278,ve_adult_vax_n_2,abersm.gmail.com,"2025-08-03 16:52:01","Age 18-59"
278,ve_adult_vax_n_3,abersm.gmail.com,"2025-08-03 16:51:54","Age 18-59"
278,ve_adult_vax_n_7,abersm.gmail.com,"2025-08-03 16:44:23","Age 18-59"
278,ve_child_vax_n,abersm.gmail.com,"2025-08-03 16:38:23","Actual age range in study: 0-17 years"
278,ve_child_vax_n_2,abersm.gmail.com,"2025-08-03 16:50:49","Age 0-17"
278,ve_child_vax_n_3,abersm.gmail.com,"2025-08-03 16:50:57","Age 0-17"
278,ve_elder_vax_n,abersm.gmail.com,"2025-08-03 16:39:09","Actual age range in study: >= 60 years"
278,ve_elder_vax_n_2,abersm.gmail.com,"2025-08-03 16:50:25","Age >= 60"
278,ve_elder_vax_n_3,abersm.gmail.com,"2025-08-03 16:50:17","Age >= 60"
278,ve_elder_vax_n_6,abersm.gmail.com,"2025-08-03 16:49:49","Age >= 60"
278,ve_elder_vax_n_7,abersm.gmail.com,"2025-08-03 17:02:17","Age >= 60"
279,population_disagg,abersm.gmail.com,"2025-08-03 16:11:20","Age not disaggregated by vaccine type"
280,ae_outcome,emeyerowit.montefiore.org,"2025-08-10 14:50:57","2 cases reported in study"
282,domain_ae_include_vax,moat0011,"2025-08-06 17:33:53","Pfizer, Sinopharm, AstraZeneca, Covishield"
286,ae_vax_type_v3,emeyerowit.montefiore.org,"2025-08-10 15:50:02",mRNA-1010
288,ae_outcome1_vax_y,flemi644,"2025-08-08 17:07:09","Noted that a retrospective analysis revealed that the 1 GBS case for BNT162b2 did not meet BCCD criteria."
289,ve_outcome_two,harleen.k.marwah.gmail.com,"2025-08-05 14:49:19","Endpoint 2 was RSV associated LRTI with severe hypoxemia"
289,ve_vax_type,harleen.k.marwah.gmail.com,"2025-08-05 14:45:05","RSV F protein nanoparticle vaccine"
290,ae_outcome,emeyerowit.montefiore.org,"2025-08-10 16:06:38","There was no significant between-group difference in the key sec­ondary endpoint of MACE (CV death, myocardial infarction and stroke) at 45 days (WR: 0.82; 95 % CI: 0.48---1.39; P = 0.46). Time-to-first event analysis for MACE showed similar results to those of the 
win ratio analysis (HR: 1.22; 95 % CI: 0.72---2.07; P = 0.47). 

At 45 days, all-cause deaths occurred in 30 (3.3 %) subjects of double-dose group and 25 (2.8 %) of the standard-dose group (HR: 1.22; 
95 % CI: 0.72---2.07; P = 0.47) and CV death had occurred in 20 (2.2%) subjects of double-dose and 14 (1.5 %) in standard-dose (HR: 1.45; 
95 % CI: 0.73---2.87; P = 0.29) (Fig. 3. c,d). 

Acute myocardial infarction occurred in 0.8 % of pa­
tients of the double-dose group and in 0.9 % of those in the late standard- 
dose group (HR: 1.16; 95 % CI: 0.42---3.19; P = 0.78); stroke had 
occurred in 0.4 % of patients of double-dose and in 0.4 % of those in the 
standard-dose group (HR: 1.01; 95 % CI: 0.25---4.04; P = 0.99"
292,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-08-10 16:24:49","Total of 27,062 hospitalizations or deaths from COVID during the season (not broken down by number who received booster)"
293,ae_incidence_yn,emeyerowit.montefiore.org,"2025-08-10 16:32:24","1707 GBS reports, but no total number of BNT162b2 vaccines given during the time period in the EU"
293,ae_incidence_yn_v2,emeyerowit.montefiore.org,"2025-08-10 16:33:05","596 GBS reports for mRNA-1273, but no total number of mRNA-1273 vaccines given in the EU during the study period"
293,ae_incidence_yn_v3,emeyerowit.montefiore.org,"2025-08-10 16:33:50","551 GBS reports following Ad26.Co2.S, but no denominator"
294,ae_incidence_yn,emeyerowit.montefiore.org,"2025-08-10 16:37:16","1 mild case reported, but no denominator can be reliably generated from this study"
297,ae_outcome1_em_ci,harleen.k.marwah.gmail.com,"2025-08-05 15:09:12","Table 3"
297,ae_vax_type,harleen.k.marwah.gmail.com,"2025-08-05 15:06:19",RSVPreF3
297,ae_vax_type_v2,harleen.k.marwah.gmail.com,"2025-08-05 15:09:51",RSVPreF
297,design,harleen.k.marwah.gmail.com,"2025-08-05 15:02:08","a test-negative case-control design  was used to estimate vaccine effectiveness (VE), and a self-controlled case series of vaccine  recipients was included to estimate vaccine-associated adverse events"
297,ve_adult_vax_n,harleen.k.marwah.gmail.com,"2025-08-05 15:16:44","Over 60: 1318/53 963 (2.4)"
297,ve_adult_vax_n_2,harleen.k.marwah.gmail.com,"2025-08-05 15:19:20","> 60: 391/18 831 (2.1)"
297,ve_adult_vax_n_3,harleen.k.marwah.gmail.com,"2025-08-05 15:21:29","60+: 469/22125 (2.1)"
297,ve_elder_em,harleen.k.marwah.gmail.com,"2025-08-05 15:18:22","60-74: 75.2 (73.0-77.2) 
75+: 75.6 (73.7-77.3)"
297,ve_elder_em_2,harleen.k.marwah.gmail.com,"2025-08-05 15:20:34","60-74: 76.9 (72.9-80.3)
75+:  76.2 (72.9-79.2)"
297,ve_elder_em_3,harleen.k.marwah.gmail.com,"2025-08-05 15:22:21","60-74: 75.2 (71.0-78.8) 
75+ 76.1 (73.2-78.7)"
297,ve_elder_vax_n,harleen.k.marwah.gmail.com,"2025-08-05 15:17:38","60-74: 561/27 923 (2.0) 
> 75: 757/26 040 (2.9)"
297,ve_elder_vax_n_2,harleen.k.marwah.gmail.com,"2025-08-05 15:20:15","60-74: 157/10181 (1.5) 
75+: 234/8650 (2.7)"
297,ve_elder_vax_n_3,harleen.k.marwah.gmail.com,"2025-08-05 15:21:57","60-74: 161/9266 (1.7) 
74+: 308/12 859 (2.4)"
298,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-08-10 16:48:42","Increased risk for long covid associated with not being fully vaccinated: (HR: 1·96, 95 % CI: 1·03-3·7, p = 0·03"
298,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-08-10 16:47:59","276 participants with COVID, including 104 with a prior COVID infection (reinfection identified during the study period).

263 were fully vaccinated

Long COVID -  87 (32 %) had symptoms lasting at least a month. A total 
of 57 (21 %) had symptoms lasting at least two months, 41 (15 %) at 
least three months, 26 (9 %) at least six months, 18 (7 %) at least nine 
months, and 15 (5 %) at least twelve months"
299,ve_child_em,stodd046,"2025-08-11 17:23:41","Did the following math to put into a 2x2 table and calculate simple VE: 
Vax(+) = 6334, Vax(-)=9733
UnVax(+) = 38865, UnVax(-)=36477"
299,ve_child_em_adj,stodd046,"2025-08-11 17:08:15","Unadjusted IVE for 7-17 yr: 40.5 (37.1-43.7)
Adjusted IVE for 6 mo - 6 yr: 45.8 (42.6-48.9)

Unadjusted IVE for 6 mo - 6 yr: 35.3 (32.3-38.2)
Adjusted IVE for 7-17 yr: 38.6 (35.7-41.5)"
299,ve_child_em_adj,stodd046,"2025-08-11 17:24:33","Did not calculate CI for our combined age group VE"
299,ve_child_vax_n,stodd046,"2025-08-11 14:12:45","(Table 2) Added 6 mo - 6 yr  test-positive groups (unvaxxed and vaxxed) with 7-17 yr test-positive groups"
301,domain_ae_include_list,emeyerowit.montefiore.org,"2025-08-10 17:12:25","VTE occurred within 90 days in 1,498 (0.11%) of the total 1,353,993 vaccinations, including 882 (0.10%) in the COVID-19 vaccination cohort and 616 (0.14%) in the influenza vaccination cohort. The rates of VTE in the three different types of COVID-19 vaccine cohorts were similar, specifically 0.09% with Pfizer, 0.11% with Moderna, and 0.08% with Janssen"
302,population_disagg,abersm.gmail.com,"2025-08-04 13:24:51","In supplement"
302,virus,abersm.gmail.com,"2025-08-04 13:22:33","Data for COVID-19 vaccine are not disaggregated by vaccine type"
303,date_start_month,abersm.gmail.com,"2025-08-04 13:29:51","Month not explicitly stated but implied based on vaccine availability."
304,ae_outcome1_otherinfo_yn,emeyerowit.montefiore.org,"2025-08-10 17:20:17","Info on presentation"
304,ae_outcome1_vax_y,emeyerowit.montefiore.org,"2025-08-10 17:21:13","8 cases of TTS = thrombosis with thrombocytopenia syndrome, of whom 3 had CVST"
306,ve_vax1_other,emeyerowit.montefiore.org,"2025-08-11 10:32:37","""About half of the 
patients were vaccinated against COVID-19 (49.2%), 
mainly with one dose (26.9%)."""
314,ve_outcome_prime_txt,emeyerowit.montefiore.org,"2025-08-11 11:11:38","""Vaccination prior to first SARS-CoV-2 infection was associated with better physical and mental health outcomes. This builds upon existing observational research demonstrating a potential benefit to vaccination prior to
SARS-CoV-2.34 Subsequently, we observed markedly better physical and mental health among those receiving multiple boosters compared with no vaccination or only
a primary vaccination series before SARS-CoV-2 infection. This supports a key protective effect of vaccination, which is more pronounced among those receiving booster vaccinations"""
321,domain_ae_include_vax,moat0011,"2025-08-12 11:10:28","BBIBP-CorV-Sinopharm 
CoronaVac-Sinovac 
BNT162b2 (Pfizer-BioNTech) 
mRNA-1273 (Moderna) 
Gam-COVID-Vac (Sputnik V) 
JNJ-78436735 ( Johnson & Johnson) 
ChAdOx1 (Oxford AstraZeneca) 
Unknown"
321,population,emeyerowit.montefiore.org,"2025-08-11 11:35:55","Not specified whether children were included"
329,domain_ae_include_vax,moat0011,"2025-08-12 11:07:06","Pfizer, Moderna, AZ"
330,population,emeyerowit.montefiore.org,"2025-08-11 20:23:38","Does not specifically state, assume all ages"
331,population,emeyerowit.montefiore.org,"2025-08-11 20:26:10","Assume all ages"
332,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-08-11 20:34:13","Table 4"
332,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-08-11 20:34:03","Table 1"
335,ae_outcome1_em_ci_4,emeyerowit.montefiore.org,"2025-08-14 11:55:05","supplementary table 24 - BNT boost of any primary series"
335,ae_outcome1_em_ci_v2,emeyerowit.montefiore.org,"2025-08-13 19:59:35","aHR for myocarditis only - may need to sum myocarditis and pericarditis"
335,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-08-13 09:52:58","Age and sex adjusted hazard ratio for week 1 after either second or booster dose"
335,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-08-14 11:53:31","supplementary table 24 - BNT booster after any primary series"
335,ae_outcome1_em_type_2,emeyerowit.montefiore.org,"2025-08-13 09:54:22","adjusted hazard ratio for BNT162b2 boost of any primary series at 1 week from booster dose"
335,ae_outcome1_em_type_2_v2,emeyerowit.montefiore.org,"2025-08-13 10:08:39","Used supplementary table 23 - booster with mRNA-1273 after any primary course adjusted hazard ratio"
335,ae_outcome1_em_type_3,emeyerowit.montefiore.org,"2025-08-13 09:54:55","adjusted hazard ratio as above"
335,ae_outcome1_em_type_3_v2,emeyerowit.montefiore.org,"2025-08-13 10:02:26","Age and sex adjusted HR, for week 1 after vaccine"
335,ae_outcome1_em_type_4,emeyerowit.montefiore.org,"2025-08-14 11:55:12","age and sex adjusted HR"
335,ae_outcome1_em_type_4_v2,emeyerowit.montefiore.org,"2025-08-13 10:09:58","Age and sex adjusted HR, using supplementary table 23 as above"
335,ae_outcome1_em_type_5,emeyerowit.montefiore.org,"2025-08-13 09:56:30","adjusted hazard ratio"
335,ae_outcome1_em_type_5_v2,emeyerowit.montefiore.org,"2025-08-13 10:03:24","age and sex adjusted HR, for weeks 0-4 after second dose"
335,ae_outcome1_em_type_6,emeyerowit.montefiore.org,"2025-08-13 09:57:11","adjusted hazard ratio, supplementary table 24"
335,ae_outcome1_em_type_6_v2,emeyerowit.montefiore.org,"2025-08-13 10:10:32","Age and sex adjusted"
335,ae_outcome1_em_type_6_v2,emeyerowit.montefiore.org,"2025-08-14 11:51:42","Supplementary table 23 as above"
335,ae_outcome1_em_type_7,emeyerowit.montefiore.org,"2025-08-13 09:58:13","adjusted hazard ratio"
335,ae_outcome1_em_type_8,emeyerowit.montefiore.org,"2025-08-13 09:57:41","adjusted hazard ratio"
335,ae_outcome1_em_type_8,emeyerowit.montefiore.org,"2025-08-14 11:56:03","supplementary table 24"
335,ae_outcome1_em_type_8_v2,emeyerowit.montefiore.org,"2025-08-13 10:11:10","age and sex adjusted"
335,ae_outcome1_em_type_8_v2,emeyerowit.montefiore.org,"2025-08-14 11:53:00","supplementary table 23 as above"
335,ae_outcome1_em_type_v2,emeyerowit.montefiore.org,"2025-08-13 10:00:48","adjusted, - just reporting value for myocarditis here. May need to calculate myocarditis + pericarditis as composite outcome, supplementary table 13"
335,ae_outcome1_em_value,emeyerowit.montefiore.org,"2025-08-13 18:12:11","for ""myocarditis"" only - may need to calculate composite of ""myocarditis"" + ""pericarditis"""
335,ae_outcome1_em_value_2,emeyerowit.montefiore.org,"2025-08-13 18:12:23","for ""myocarditis"" only - may need to calculate composite of ""myocarditis"" + ""pericarditis"""
335,ae_outcome1_em_value_2,emeyerowit.montefiore.org,"2025-08-14 11:54:29","supplementary table 24 - BNT booster after any primary series"
335,ae_outcome1_em_value_2_v2,emeyerowit.montefiore.org,"2025-08-13 10:08:59","Weeks 0-4 after booster"
335,ae_outcome1_em_value_2_v2,emeyerowit.montefiore.org,"2025-08-13 10:09:25","just reporting myocarditis, may need to use composite of myocarditis + pericarditis"
335,ae_outcome1_em_value_3,emeyerowit.montefiore.org,"2025-08-13 09:55:50","Supplementary Table 12"
335,ae_outcome1_em_value_4_v2,emeyerowit.montefiore.org,"2025-08-13 10:10:16","Risk at 1 week after booster"
335,ae_outcome1_em_value_6_v2,emeyerowit.montefiore.org,"2025-08-13 10:10:56","week 1 after booster"
335,ae_outcome1_em_value_7_v2,emeyerowit.montefiore.org,"2025-08-13 10:04:37","unable to run model"
335,ae_outcome1_em_value_8_v2,emeyerowit.montefiore.org,"2025-08-13 10:11:16","weeks 0-4 after booster"
335,ae_outcome1_em_value_v2,emeyerowit.montefiore.org,"2025-08-13 10:01:27","Collapsed time period for weeks 0-4 after second dose"
335,ae_outcome1_unvax_y_2,emeyerowit.montefiore.org,"2025-08-13 10:24:18","I don't think we have this number for booster cohort"
335,ae_outcome1_unvax_y_2_v2,emeyerowit.montefiore.org,"2025-08-13 10:21:15","I don't think we have this number for the booster cohort"
335,ae_outcome1_unvax_y_3_v2,emeyerowit.montefiore.org,"2025-08-13 10:22:18","supplmentary table 4 - ""no vaccine"""
335,ae_outcome1_unvax_y_4_v2,emeyerowit.montefiore.org,"2025-08-13 10:22:52","I don't think this number is available in the data provided"
335,ae_outcome1_unvax_y_v2,emeyerowit.montefiore.org,"2025-08-13 10:18:46","supplementary table 4 - ""no vaccine"""
335,ae_outcome1_unvax_y_v2,emeyerowit.montefiore.org,"2025-08-13 19:59:10","sum myocarditis + pericarditis"
335,ae_outcome1_vax_n,emeyerowit.montefiore.org,"2025-08-13 09:50:05","Used total n from supplementary tables 1 and 2"
335,ae_outcome1_vax_y_v2,emeyerowit.montefiore.org,"2025-08-13 10:17:50","summing doses 1+2 totals at bottom of supplementary table 4"
338,ae_incidence_yn_v2,emeyerowit.montefiore.org,"2025-08-12 20:28:12","SAE8 in Table S12 - man in his 20s, symptoms started 4 days after second dose, 2 doses were spaced 1 month apart"
338,design,emeyerowit.montefiore.org,"2025-08-12 20:22:38","28 days after last administration of October 26, 2021"
339,date_start_year,abersm.gmail.com,"2025-08-03 17:23:26","Specifically for COVID-19 vaccination subgroup"
343,domain_ae_include_list,scottja.stanford.edu,"2025-08-11 23:41:45","This French pharmacovigilance study and nationwide survey found a reporting rate (RR) for new-onset polymyalgia rheumatica (PMR) of 7.1 cases per 1,000,000 vaccinated persons aged >50 (179 cases total). The RR for giant cell arteritis (GCA) was 2.1 cases per 1,000,000 persons (54 cases total). The median time from vaccination to symptom onset was 10 days for PMR and 7 days for GCA."
343,domain_ae_include_vax,moat0011,"2025-08-15 11:43:17","Also AZ"
343,population,moat0011,"2025-08-15 11:44:13",52-94
344,domain_ae_include_vax,moat0011,"2025-08-07 11:41:00","Ad26.RSV.preF/RSV preF protein vaccine; not approved for use in the US"
346,ae_comparator1_other,emeyerowit.montefiore.org,"2025-08-13 20:30:57","Study uses reporting odds ratio (ROR): ""OR was calculated using the following formula: ROR = (a/b)/(c/d), where ""a"" represents the number of reports for a certain adverse drug reaction, ""b"" is the number of reports for all other ADRs with a specific drug, ""c"" is the number of all reports for certain 
ADRs not related to a specific drug, and ""d"" is the number of all reports not related to both specific ADRs and drugs."""
346,ae_incidence_yn,emeyerowit.montefiore.org,"2025-08-13 20:32:54","Influenza vaccines had the highest association with GBS (ROR, 77.91 [95% CI, 75.30-80.62]"
351,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-08-13 20:52:09","those who received 4 vaccines"
351,ve_overall_vax_n_2,emeyerowit.montefiore.org,"2025-08-13 20:53:58","those who received 4 (reference group), table 4"
352,ae_outcome_5,emeyerowit.montefiore.org,"2025-08-07 20:31:22","NOT STRICTLY MI"
355,domain_ae_include_vax,moat0011,"2025-08-07 12:17:12","MVA-BN-RSV vaccine"
370,date_end_year,stodd046,"2025-08-15 16:03:17","study end date"
375,ve_adult_vax_n,stodd046,"2025-08-21 15:12:43","""Within those in a clinical risk group aged 18-64 years"""
378,domain_ae_include_vax,stodd046,"2025-08-21 14:16:18","Other: ChAdOx1"
378,population_disagg,stodd046,"2025-08-21 14:17:55","18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+"
385,domain_ae_include_vax,moat0011,"2025-08-21 10:28:14","Also AZ and Novavax"
388,ae_outcome,stodd046,"2025-08-21 15:48:40","""Apart from the expected AEs, the following serious unexpected AEs were reported within 6 weeks of vaccination: 1 cerebral sinus thrombosis"
398,ve_adult_em_adj,stodd046,"2025-08-21 14:00:44","50-64 year old"
399,ve_adult_vax_n,emeyerowit.montefiore.org,"2025-08-13 21:08:32","ages 3-9 years"
399,ve_adult_vax_n_2,emeyerowit.montefiore.org,"2025-08-13 21:11:52","60-69 years"
399,ve_child_vax_n,emeyerowit.montefiore.org,"2025-08-13 21:07:52","6 months to 2 years"
399,ve_child_vax_n_2,emeyerowit.montefiore.org,"2025-08-13 21:11:01","18-59 years"
399,ve_elder_vax_n,emeyerowit.montefiore.org,"2025-08-13 21:09:13","ages 10-17 years"
399,ve_elder_vax_n_2,emeyerowit.montefiore.org,"2025-08-13 21:12:22","70+ years"
400,domain_ae_include_list,stodd046,"2025-08-21 14:04:59","self-reported reactogenicity reports in Table 2"
400,population,emeyerowit.montefiore.org,"2025-08-13 21:15:51","Not specified whether children were included"
401,ae_incidence_yn,stodd046,"2025-08-12 13:32:52","The authors report the number of events and the relative incidence of GBS in 1-42 days of exposure (Figure 1)."
401,ae_incidence_yn,stodd046,"2025-08-12 13:35:22","Dose 1: 93 events, RI=1.1 (0.91,1.4)
Dose 2: 107 events, RI=1.0 (0.83,1.3) 
Dose 3: 78 events, RI= 0.92 (0.70,1.2)"
401,ae_incidence_yn_v2,stodd046,"2025-08-12 13:38:21","Dose 1: 14 events, RI=1.2 (0.68,2.1)
Dose 2: 25 events, RI=1.3 (0.84,2.0)
Dose 3: 35 events, RI= 0.98 (0.64,1.5)"
401,ae_incidence_yn_v3,stodd046,"2025-08-12 13:39:20","Dose 1: 10 events, RI=2.4 (1.2,5.0)*"
402,ae_outcome,emeyerowit.montefiore.org,"2025-08-14 17:13:56","Risk following dose 1"
402,ae_outcome1_describe_4,emeyerowit.montefiore.org,"2025-08-14 20:41:56","supplementary table 2"
402,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-08-14 17:16:06","Adjusted odds ratio"
402,ae_outcome1_em_type_2,emeyerowit.montefiore.org,"2025-08-14 20:08:55",adjusted
402,ae_outcome1_em_type_2_v2,emeyerowit.montefiore.org,"2025-08-14 20:27:32",adjusted
402,ae_outcome1_em_type_3,emeyerowit.montefiore.org,"2025-08-14 20:15:32",adjusted
402,ae_outcome1_em_type_3_v2,emeyerowit.montefiore.org,"2025-08-14 20:35:49","adjusted odds ratio"
402,ae_outcome1_em_type_4,emeyerowit.montefiore.org,"2025-08-14 20:42:56",adjusted
402,ae_outcome1_em_type_4_v2,emeyerowit.montefiore.org,"2025-08-14 20:48:50",adjusted
402,ae_outcome1_em_type_5_v2,emeyerowit.montefiore.org,"2025-08-14 20:49:55",adjusted
402,ae_outcome1_em_type_6,emeyerowit.montefiore.org,"2025-08-14 20:21:04",adjusted
402,ae_outcome1_em_type_6_v2,emeyerowit.montefiore.org,"2025-08-14 20:51:25",adjusted
402,ae_outcome1_em_type_8,emeyerowit.montefiore.org,"2025-08-14 20:23:33",adjusted
402,ae_outcome1_em_type_v2,emeyerowit.montefiore.org,"2025-08-14 20:26:25",adjusted
402,ae_outcome1_unvax_y_5,emeyerowit.montefiore.org,"2025-08-14 20:44:08",adjusted
402,ae_outcome1_vax_y,emeyerowit.montefiore.org,"2025-08-14 20:00:13","Supplementary Table 3"
402,ae_outcome1_vax_y_6,emeyerowit.montefiore.org,"2025-08-14 20:46:44",males
402,ae_outcome1_vax_y_6_v2,emeyerowit.montefiore.org,"2025-08-14 20:50:49",males
402,date_end_month,flemi644,"2025-08-15 17:49:23","changed to November (Results -> vaccines received)"
405,epi_hospitalization_covid,flemi644,"2025-08-12 10:50:04","Note that I decided to exclude ED since data on whether those ended up being outpatient or hospitalized was not provided. Data pulled from Supp figure (table) 3"
405,epi_sample_covid,flemi644,"2025-08-12 10:51:17","ED visits excluded. See comment on hospitalization rate."
406,ve_adult_em,scottja.stanford.edu,"2025-08-15 02:00:24","The study reports VE for 18-49 and 50-64 year olds separately, but not for the combined 18-64 group."
406,ve_adult_em_ci,scottja.stanford.edu,"2025-08-15 02:00:50","The study reports the following separately:
VE for 18-49 years: 53% (95% CI, 34%-67%)
VE for 50-64 years: 47% (95% CI, 31%-60%)"
406,ve_adult_unvax_n,scottja.stanford.edu,"2025-08-15 01:59:54","(This is 1389 controls from the 18-49 group + 1748 from the 50-64 group)"
406,ve_adult_unvax_y,scottja.stanford.edu,"2025-08-15 02:00:07","(This is 364 vaccinated controls from the 18-49 group + 653 from the 50-64 group)"
406,ve_adult_vax_n,scottja.stanford.edu,"2025-08-15 01:59:31","(This is 314 cases from the 18-49 group + 351 cases from the 50-64 group)."
406,ve_adult_vax_y,scottja.stanford.edu,"2025-08-15 01:59:42","(This is 52 vaccinated cases from the 18-49 group + 96 from the 50-64 group)."
406,ve_vax_type,scottja.stanford.edu,"2025-08-15 01:55:14","data on the type of influenza vaccine received were not collected, precluding comparative effectiveness analyses by vaccine type"
407,epi_sample_covid,emeyerowit.montefiore.org,"2025-08-16 20:44:29","3080 BA.2.86 lineage (eg JN.1) and 4614 non-BA.2.76 lineage infections"
409,ae_outcome,stodd046,"2025-08-20 14:48:04","26 cases, not disaggregated by vaccine type."
409,ae_outcome_v2,stodd046,"2025-08-20 14:48:12","26 cases, not disaggregated by vaccine type."
409,domain_ae_inc_other_txt,stodd046,"2025-08-20 14:43:07","""Among the SAE reports, a total of 8,723 non-unique AEs and 1,907 unique AEs were identified. The most commonly reported AEs included death (N = (250)), dyspnoea (N = 115), and COVID-19 (N = 107)."""
412,exclude,flemi644,"2025-08-13 10:44:45","no negative controls and only comparing to non-US licensed vaccines for AEs not of special interest. May consider excluding. Leaving for second reviewer opinion."
412,population,flemi644,"2025-08-13 10:34:34","All adults 18+"
414,population_other,flemi644,"2025-08-13 17:28:06","Note that VE is not disaggregated by 1-64 and 65+ even though some numbers are given. Not enough to calculate ve"
414,ve_adult_em_adj,flemi644,"2025-08-13 17:16:08","reported as ""similar to overall"""
414,ve_adult_em_adj_2,flemi644,"2025-08-13 17:22:20","only 7-59d post vaccine"
414,ve_elder_em_adj,flemi644,"2025-08-13 17:17:07","Reported as ""similar to overall"""
414,ve_elder_em_adj_2,flemi644,"2025-08-13 17:26:41","7-59d post-vaccine only"
416,ae_outcome,flemi644,"2025-08-15 11:00:56","Myocard and perar is pooled"
416,domain_ae_include_vax,stodd046,"2025-08-20 14:53:37","Other = ChAdOx1 nCoV-19"
417,population,flemi644,"2025-08-15 15:32:55","Adults 60+ years"
417,ve_em_type,stodd046,"2025-08-20 15:13:23","IRR by wave is reported in the supplementary but uses wave 10 as the reference group."
417,ve_overall_em,flemi644,"2025-08-15 15:52:46","Hybrid vs VUPI"
417,ve_overall_em,flemi644,"2025-08-15 15:56:59","calculated using person-days at risk."
417,ve_overall_unvax_n,flemi644,"2025-08-15 15:55:03","# VUPI patients with severe disease"
417,ve_overall_vax_n,flemi644,"2025-08-15 15:54:46","# hybrid patients with severe disease"
417,ve_overall_vax_n,stodd046,"2025-08-20 15:11:50","For the total study period, not just wave 10 which spans into 2024. They have graphs depicting the disaggregated age and wave date but do not report the numbers."
418,ae_vax_type,flemi644,"2025-08-15 16:59:00","Extracting the pooled pfizer/moderna data due to lack incidence rate data"
419,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-08-16 13:48:31","Table 3 has IRR"
419,ae_outcome1_em_value,stodd046,"2025-08-21 10:15:53","This is the IRR for GBS among Medicare FFS population."
419,ae_outcome1_unvax_n,emeyerowit.montefiore.org,"2025-08-16 13:44:56","adjusted person years - 1,463,721.80"
419,ae_outcome1_unvax_n_2,emeyerowit.montefiore.org,"2025-08-16 13:52:53","adjusted person years:  1,448,623.87"
419,ae_outcome1_unvax_n_3,emeyerowit.montefiore.org,"2025-08-16 15:01:52","1,467,906.74"
419,ae_outcome1_unvax_n_4,emeyerowit.montefiore.org,"2025-08-16 15:03:50","1,467,984.36"
419,ae_outcome1_unvax_n_5,emeyerowit.montefiore.org,"2025-08-16 15:06:09","1,480,427.42"
419,ae_outcome1_vax_n,emeyerowit.montefiore.org,"2025-08-16 13:44:36","adjusted person years -   1,318,301.10"
419,ae_outcome1_vax_n_2,emeyerowit.montefiore.org,"2025-08-16 13:52:18","adjusted person-years: 1,306,238.98"
419,ae_outcome1_vax_n_3,emeyerowit.montefiore.org,"2025-08-16 15:01:57","1,322,518.91"
419,ae_outcome1_vax_n_4,emeyerowit.montefiore.org,"2025-08-16 15:03:45","1,322,453.20"
419,ae_outcome1_vax_n_5,emeyerowit.montefiore.org,"2025-08-16 15:05:50","1,331,496.86"
421,population,emeyerowit.montefiore.org,"2025-08-16 20:16:26","Does not specify whether children were included"
423,ae_outcome,abersm.gmail.com,"2025-07-30 13:00:42","Non-hemorrhagic stroke"
423,ae_outcome_2,abersm.gmail.com,"2025-07-30 13:05:39",TIA
423,ae_outcome_2_v2,abersm.gmail.com,"2025-07-30 13:12:29",TIA
423,ae_outcome_3_v2,abersm.gmail.com,"2025-07-30 13:12:48","Non-hemorrhagic stroke"
423,ae_outcome_4,abersm.gmail.com,"2025-07-30 13:07:39","TIA or non-hemorrhagic stroke"
423,ae_outcome_4_v2,abersm.gmail.com,"2025-07-30 13:13:11","Non-hemorrhagic stroke or TIA"
423,ae_outcome_v2,abersm.gmail.com,"2025-07-30 13:12:14","Hemorrhagic stroke"
423,ae_outcome1_describe_3,abersm.gmail.com,"2025-07-30 13:07:06","Non-hemorrhagic stroke"
423,ae_vax_type,abersm.gmail.com,"2025-07-30 13:10:48","Bivalent Pfizer-BioNTech BNT162b2; WT/OMI BA.4/BA.5"
423,ae_vax_type_v2,abersm.gmail.com,"2025-07-30 13:11:40","Bivalent Moderna mRNA-1273.222"
423,domain,abersm.gmail.com,"2025-07-30 13:47:10","Not formally a co-administration study but analyses are stratified by whether patient received influenza vaccine (see raw data in supplement)"
423,domain_ae_include_yn,abersm.gmail.com,"2025-07-30 12:48:09","Data in article/supplement are disaggregated by type of stroke"
426,domain_ae_include_list,stodd046,"2025-08-21 10:39:17","""There was one serious AEFI (angina pectoris), and all other AEFI were non-serious"""
428,ae_outcome1_em_type_2,ncmccann.bu.edu,"2025-08-07 20:33:47","Not sure why they give a RR for preterm birth but not weight"
430,date_start_year,abersm.gmail.com,"2025-08-03 18:06:13","Date of vaccination"
430,setting,abersm.gmail.com,"2025-08-03 18:06:16","Date of vaccination"
436,study_label,stodd046,"2025-08-21 16:38:44","EXCLUDED FROM FURTHER REVIEW"
449,domain_ae_include_vax,scottja.stanford.edu,"2025-08-15 02:59:52","Standard-dose (VaxigripTetra), MF59-adjuvanted (Fluad), High-dose (Fluzone-HD)"
449,ve_overall_vax_n,scottja.stanford.edu,"2025-08-15 03:07:43","This is the total number of participants who received a vaccine across all three groups"
449,ve_overall_vax_y,scottja.stanford.edu,"2025-08-15 03:07:59","This is the total number of PCR-confirmed influenza cases across all three vaccine groups combined"
449,ve_vax_type_v2,scottja.stanford.edu,"2025-08-15 03:09:39","MF59-adjuvanted (Fluad)."
454,date_end_month,flemi644,"2025-08-22 12:29:32","Edited date based on section 2.3"
456,study_label,stodd046,"2025-08-21 16:44:17","EXCLUDED FROM FURTHER REVIEW"
457,population,emeyerowit.montefiore.org,"2025-08-20 14:26:56","Age range not mentioned but appears to be only adults"
458,coadmin_sero,emeyerowit.montefiore.org,"2025-08-22 12:42:58","Model-adjusted GMRs (95% CI) for coad-
ministration to separate-administration were
0.83 (0.77, 0.89) for full-length S-binding IgG
levels and 0.89 (0.77, 1.04), 0.95 (0.83, 1.09),
0.96 (0.85, 1.09), and 1.00 (0.89, 1.13) for the
four strain-specific HAI titers (Fig. 3). The pre-
specified noninferiority criterion was met for
full-length S-binding IgG levels and HAI titers
for each of the four influenza assay strains
(lower bound 95% CI [0.67)"
461,date_end_year,flemi644,"2025-08-14 16:08:48","Vaccine product and lab assay timing indicate the 2020/21 influenza season; Results section says ""between November and December 2021,"" which is almost certainly a typographical error given invitations in Nov-Dec 2020 and assays in March 2021."
464,ae_outcome,emeyerowit.montefiore.org,"2025-08-22 13:02:15","Level of Certainty 1-2"
464,ae_outcome_2,emeyerowit.montefiore.org,"2025-08-22 13:03:10","Level of confidence 1-4"
464,ae_outcome_2_v2,emeyerowit.montefiore.org,"2025-08-22 13:12:10","LOC 1-4"
464,ae_outcome_2_v3,emeyerowit.montefiore.org,"2025-08-22 13:14:54","LOC 1-4"
464,ae_outcome_v2,emeyerowit.montefiore.org,"2025-08-22 13:11:38","LOC 1-2"
464,ae_outcome_v3,emeyerowit.montefiore.org,"2025-08-22 13:14:10","LOC 1-2"
464,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-08-22 13:02:38","Relative incidence"
464,ae_outcome1_em_type_2,emeyerowit.montefiore.org,"2025-08-22 13:03:21","Relative incidence"
464,ae_outcome1_em_type_2_v2,emeyerowit.montefiore.org,"2025-08-22 13:12:28","Relative incidence"
464,ae_outcome1_em_type_2_v3,emeyerowit.montefiore.org,"2025-08-22 13:15:12","Relative incidence"
464,ae_outcome1_em_type_v2,emeyerowit.montefiore.org,"2025-08-22 13:11:30","Relative incidence"
464,ae_outcome1_em_type_v3,emeyerowit.montefiore.org,"2025-08-22 13:14:27","Relative incidence"
465,ae_outcome1_em_type_2_v3,emeyerowit.montefiore.org,"2025-08-24 16:19:27","frequency per million doses"
465,ae_outcome1_em_type_v2,emeyerowit.montefiore.org,"2025-08-24 16:16:24","frequency per million doses"
465,ae_outcome1_em_type_v3,emeyerowit.montefiore.org,"2025-08-24 16:18:24","frequency per million doses"
465,ae_outcome1_em_value,emeyerowit.montefiore.org,"2025-08-24 16:11:37","per million"
466,ae_outcome1_em_type_2,emeyerowit.montefiore.org,"2025-08-24 16:36:16","Rate per million doses"
466,ae_outcome1_em_type_2_v2,emeyerowit.montefiore.org,"2025-08-24 16:41:40","rate per million doses"
466,ae_outcome1_em_type_2_v3,emeyerowit.montefiore.org,"2025-08-24 16:48:45","rate per million doses"
466,ae_outcome1_em_type_3,emeyerowit.montefiore.org,"2025-08-24 16:36:48","rate per million doses"
466,ae_outcome1_em_type_3_v2,emeyerowit.montefiore.org,"2025-08-24 16:42:30","rate per million doses"
466,ae_outcome1_em_type_3_v3,emeyerowit.montefiore.org,"2025-08-24 16:49:26","rate per million doses"
466,ae_outcome1_em_type_4,emeyerowit.montefiore.org,"2025-08-24 16:37:34","rate per million doses"
466,ae_outcome1_em_type_4_v2,emeyerowit.montefiore.org,"2025-08-24 16:43:14","rate per million doses"
466,ae_outcome1_em_type_4_v3,emeyerowit.montefiore.org,"2025-08-24 16:50:16","rate per million doses"
466,ae_outcome1_em_type_5,emeyerowit.montefiore.org,"2025-08-24 16:38:31","Per million doses"
466,ae_outcome1_em_type_5_v2,emeyerowit.montefiore.org,"2025-08-24 16:44:08","rate per million doses"
466,ae_outcome1_em_type_5_v3,emeyerowit.montefiore.org,"2025-08-24 16:51:10","rate per million doses"
466,ae_outcome1_em_type_v2,emeyerowit.montefiore.org,"2025-08-24 16:40:15","Myopericarditis per million doses"
466,ae_outcome1_em_type_v3,emeyerowit.montefiore.org,"2025-08-24 16:45:30","rate per million doses"
466,ae_outcome1_em_value,emeyerowit.montefiore.org,"2025-08-24 16:35:10","Rate of myopericarditis per million doses"
467,domain_ae_include_list,flemi644,"2025-08-12 16:44:01","DVT and/or PE"
467,population,calba1.mgh.harvard.edu,"2025-08-12 18:33:24","Immunocompromised adults are also 18-64 and adults >=65 years"
469,population_disagg,stodd046,"2025-08-12 16:20:23","Below 40 group, 40+ group"
470,population,flemi644,"2025-08-18 11:12:36","Adults 18-64 = All adults 18+"
474,population,flemi644,"2025-08-18 12:23:30","adults 65+ = adults 65-79"
474,ve_elder_unvax_n,flemi644,"2025-08-18 12:33:28","unvaccinated, person-months at risk"
474,ve_elder_unvax_n_2,flemi644,"2025-08-18 12:40:07","unvaccinated; person months at risk"
474,ve_elder_unvax_y,flemi644,"2025-08-18 12:33:44","unvaccinated events"
474,ve_elder_unvax_y_2,flemi644,"2025-08-18 12:40:15","unvaccinated cases"
474,ve_elder_vax_n,flemi644,"2025-08-18 12:34:24","vaccinated, person-months at risk"
474,ve_elder_vax_n_2,flemi644,"2025-08-18 12:39:49","vaccinated; person months at risk"
474,ve_elder_vax_y,flemi644,"2025-08-18 12:34:35","vaccinated events"
474,ve_elder_vax_y_2,flemi644,"2025-08-18 12:39:56","vaccinated cases"
474,ve_other_unvax_n,flemi644,"2025-08-18 12:37:51","unvaccinated; person months at risk"
474,ve_other_unvax_n_2,flemi644,"2025-08-18 12:40:46","unvaccinated; person months at risk"
474,ve_other_unvax_y,flemi644,"2025-08-18 12:38:00","unvaccinated cases"
474,ve_other_unvax_y_2,flemi644,"2025-08-18 12:40:52","unvaccinated cases"
474,ve_other_vax_n,flemi644,"2025-08-18 12:36:46","vaccinated; person months at risk"
474,ve_other_vax_n_2,flemi644,"2025-08-18 12:40:29","vaccinated; ; person months at risk"
474,ve_other_vax_y,flemi644,"2025-08-18 12:37:05","vaccinated cases"
474,ve_other_vax_y_2,flemi644,"2025-08-18 12:40:38","vaccinated cases"
477,population_disagg,abersm.gmail.com,"2025-08-02 12:56:04","Individual patient data provided"
478,ae_outcome,emeyerowit.montefiore.org,"2025-08-24 19:35:05","Note composite outcome of neurologic outcomes other than epilepsy"
479,date_start_year,stodd046,"2025-08-12 16:08:19","When Vigilbase was started"
479,design,stodd046,"2025-08-12 16:10:07",Pharmacovigilance
479,domain_ae_include_vax,scottja.stanford.edu,"2025-08-24 23:22:27","The study disaggregates reports for COVID-19 mRNA, Ad5-vectored COVID-19, and inactivated whole-virus COVID-19 vaccines. It also investigates Influenza vaccines."
480,population,arpey001,"2025-08-08 14:11:16","Adults >=60 years"
481,coadmin_ae_yn,stodd046,"2025-08-20 11:42:27","no difference - number of vaccine-related AEs was 171 in concomitant group and 170 in sequential group"
481,coadmin_pop1_n_2,stodd046,"2025-08-20 11:40:07","In the PCV15 concomitant group, one participant of the 210 that received a COVID shot (errantly?) received the PPSV23 vaccine, so number of participants in this group reduced to 209"
481,coadmin_vax2_type,flemi644,"2025-08-18 15:40:57","Concomitant arm (Day 1): mRNA-1273 + PPSV23; placebo on Day 30.

Sequential arm: mRNA-1273 + placebo on Day 1; PPSV23 on Day 30."
481,coadmin_vax2_type_2,flemi644,"2025-08-18 15:41:58","Concomitant arm (Day 1): mRNA-1273 + PCV15; placebo on Day 30.

Sequential arm: mRNA-1273 + placebo on Day 1; PCV15 on Day 30."
482,ae_comparator,stodd046,"2025-08-20 11:51:01","Of the 19 cases, 16 had received mRNA vaccines and 3 had not. So the unvaccinated cases are the comparator group."
482,ae_outcome1_otherinfo_yn,stodd046,"2025-08-20 11:58:30","for each case the following are reported: age, sex, stroke diagnosis, tissue sample origin, history of previous covid infection, history of mRNA vaccination, number of vaccines, time from last vaccination to surgery, and the immunostaining profile for spike protein/nucleocapsid"
482,ae_outcome1_unvax_y,flemi644,"2025-08-18 16:21:56","positive spike protein/nucleocapsid IHC = COVID-related"
482,ae_outcome1_vax_y,flemi644,"2025-08-18 16:18:00","positive spike protein/nucleocapsid IHC = COVID-related"
482,ae_vax_type,stodd046,"2025-08-20 11:48:37","mRNA vaccines for SARS-CoV-2, such as BNT162b2 (BioNTech-Pfizer) and
mRNA-1273 (Moderna)"
486,population,abersm.gmail.com,"2025-08-03 17:43:36","Study states ""adults"" were included (age criteria not specified)"
488,domain_ae_include_yn,flemi644,"2025-08-20 18:15:35","ITP reported, but not by vaccine brand (study includes non-U.S. products)"
488,population,flemi644,"2025-08-20 18:09:54","Children 5-17"
493,coadmin_pop1_n,emeyerowit.montefiore.org,"2025-08-24 19:55:27","35 received ipsilateral and 81 contralateral vaccination"
495,ve_adult_vax_n_5,flemi644,"2025-08-12 17:52:45","For thrombolytic events, 18-64 = all adults (no age disaggregation)"
496,population_disagg,abersm.gmail.com,"2025-08-03 17:33:24","Individual patient data provided"
497,population_disagg,abersm.gmail.com,"2025-08-03 17:36:47","Individual patient data provided"
498,comments,calba1.mgh.harvard.edu,"2025-08-12 19:11:51","Counts and other AEs reported in Table S2 (added file to Covidence). Ns suggest denominator is 108. Also reports fatigue (n = 15, 13.9%), headache (4, 3.7%), chills and shivers (2, 1.9%), increased body temp (2, 1.9%), diarrhea (1, 0.9%), N/V (1, 0.9%), and arthralgias/back pain (1, 0.9%)."
498,date_end_year,calba1.mgh.harvard.edu,"2025-08-12 19:05:04","Enrollment was between 10/2021 and 12/2021 but AE data was collected at 2-4 weeks post-vaccination - so could extend into 1/2022"
498,date_end_year,flemi644,"2025-08-12 19:54:10",adjusted
498,population,calba1.mgh.harvard.edu,"2025-08-12 19:06:05","Also includes adults >65 (although not stratified data is not presented). IQR is 49-68 so majority are in the 18-64 bucket - I think okay as is extracted."
498,population,flemi644,"2025-08-12 19:53:40",fixed
500,population_disagg,abersm.gmail.com,"2025-08-03 17:29:39","Individual patient data provided"
503,population_disagg,abersm.gmail.com,"2025-08-02 12:35:54","Individual patient data provided in article."
504,ve_adult_vax_n,scottja.stanford.edu,"2025-08-15 02:47:42","The paper does not provide the raw numbers of cases and controls stratified by both age group and vaccination status."
504,ve_ic_vax_n,scottja.stanford.edu,"2025-08-15 02:51:40","The entire study population consists of immunocompromised individuals (solid organ transplant recipients). Therefore, the data for the ""immunocompromised"" group is the same as the data for the ""overall"" population."
506,domain,harleen.k.marwah.gmail.com,"2025-08-12 10:33:35","non-US epi"
510,coadmin_vax_prime_other,stodd046,"2025-08-22 11:27:57","Both Pfizer and Moderna are approved in Italy (study location)"
512,design,stodd046,"2025-08-26 13:46:29","""Briefly, three of the multicentre studies (EU-H, EU-PC and UK-PC) used prospective patient recruitment, while five studies used electronic database linkage (DK-H, DK-PC, EN-H, NI-H, SC-H)."""
512,domain_ve_num,stodd046,"2025-08-26 13:41:34","This study pools 8 different studies across 17 countries and reports the vaccine types used nationally or in the study for each, sometimes dependent on age,. These include QIV (plus variations aQIV, QIV-HD, QIVc), LIAV, and TIV but VE estimates are not disaggregated by type."
512,ve_child_vax_n,stodd046,"2025-08-26 14:18:55","0-17 years"
512,ve_child_vax_n_2,stodd046,"2025-08-26 14:25:05","6 mo -17 years"
512,ve_child_vax_n_3,stodd046,"2025-08-26 14:32:26","2-17 years"
512,ve_child_vax_n_4,stodd046,"2025-08-26 14:37:33","Age group not included here"
512,ve_child_vax_n_5,stodd046,"2025-08-26 14:40:56","2-17 years"
512,ve_child_vax_n_6,stodd046,"2025-08-26 14:46:00","0-17 years"
512,ve_child_vax_n_7,stodd046,"2025-08-26 14:49:30","Pediatric data not reported for this study"
512,ve_child_vax_n_8,stodd046,"2025-08-26 14:52:19","2-17 years"
512,ve_outcome_eight,stodd046,"2025-08-26 14:51:45","Scotland Hospital (SC-H)"
512,ve_outcome_five,stodd046,"2025-08-26 14:40:26","England Hospital (EN-H)"
512,ve_outcome_four,stodd046,"2025-08-26 14:37:13","Denmark Hospital (DK-H)"
512,ve_outcome_prime,stodd046,"2025-08-26 14:18:44","Denmark Primary Care (DK-PC)"
512,ve_outcome_seven,stodd046,"2025-08-26 14:49:03","Northern Ireland Hospital (NI-H)"
512,ve_outcome_six,stodd046,"2025-08-26 14:44:10","European Union Hospital (EU-H)"
512,ve_outcome_six,stodd046,"2025-08-26 14:45:20","EU VEBIS multicountry hospital network (EU-H: six of 10 countries contributing to the interim analysis)"
512,ve_outcome_three,stodd046,"2025-08-26 14:31:54","United Kingdom (UK) Primary Care (UK-PC:
four countries)"
512,ve_outcome_two,stodd046,"2025-08-26 14:23:50","European Union (EU) Vaccine Effectiveness, Burden and Impact Studies (VEBIS) multi-country primary care network (EU-PC: eight of 10 countries contributing to the interim analysis)"
516,ve_outcome_num,scottja.stanford.edu,"2025-08-25 01:14:17","combined event of ICU admission/mortality"
516,ve_overall_em,scottja.stanford.edu,"2025-08-25 01:17:06","The study reports a hazard ratio"
516,ve_overall_em_ci,ejholmes,"2025-08-25 10:21:05","p = 0.017"
516,ve_overall_vax_n,scottja.stanford.edu,"2025-08-25 01:16:00","It's a retrospective observational cohort study"
517,ae_incidence_yn,flemi644,"2025-08-14 17:46:01","denominator for IRR calculations appears to be person-days outside of the determined post-vaccine risk-window for the same patients."
517,ae_incidence_yn_2,flemi644,"2025-08-14 17:46:09","denominator for IRR calculations appears to be person-days outside of the determined post-vaccine risk-window for the same patients."
517,ae_outcome1_otherinfo_yn,flemi644,"2025-08-14 17:44:14","IRR rates"
517,ae_outcome1_otherinfo_yn_2,flemi644,"2025-08-14 17:44:21","IRR rates"
517,ae_vax_type,flemi644,"2025-08-14 17:27:36","Pooled Pfizer and Moderna"
517,population,flemi644,"2025-08-14 17:12:12","children 12-17"
525,ve_elder_vax_n,abersm.gmail.com,"2025-08-02 12:01:00","Data from table 2"
525,ve_elder_vax_n_2,abersm.gmail.com,"2025-08-02 12:06:40","Data from table 2"
525,ve_other_vax_n,abersm.gmail.com,"2025-08-02 12:01:06","Data from table 2"
525,ve_other_vax_n_2,abersm.gmail.com,"2025-08-02 12:06:45","Data from table 2"
525,ve_overall_vax_n,abersm.gmail.com,"2025-08-02 12:08:31","Data from table 2"
525,ve_overall_vax_n_2,abersm.gmail.com,"2025-08-02 12:10:37","Data from table 2"
525,ve_overall_vax_n_3,abersm.gmail.com,"2025-08-02 12:11:52","Data from table 2"
527,domain_ae_include_vax,moat0011,"2025-08-12 10:31:19","Pfizer, AZ, Sinovac"
528,population,moat0011,"2025-08-12 10:18:24",">12 yo"
530,ae_outcome1_vax_y,stodd046,"2025-08-22 13:01:58","I think this is 65+ only ""When we restricted the analysis to patients 65 years and older who
received the bivalent Pfizer vaccine-based on the VSD's RCA signal
detection- we identified 12 cases with an ICD-10-CM in the primary
position and all were confirmed: PPV = 100 % (95 % CI, 73.5-100)."""
530,ae_outcome1_vax_y_v2,stodd046,"2025-08-22 13:15:25","was co-administered with high-dose flu vaccine same day"
535,design,moat0011,"2025-08-22 12:29:08","""self controlled case series"""
537,ve_overall_em_2,flemi644,"2025-08-20 19:07:41","calculated by modelling infections over time (Cox model; Simon-Makuch plot)"
537,ve_overall_em_3,flemi644,"2025-08-20 19:07:48","calculated by modelling infections over time (Cox model; Simon-Makuch plot)"
537,ve_overall_vax_n,flemi644,"2025-08-20 18:59:33","Total number of employees vaccinated: 7978
Not vaccinated: 40323"
541,ve_adult_vax_n,emeyerowit.montefiore.org,"2025-08-21 15:23:47",20-64
541,ve_adult_vax_n_2,emeyerowit.montefiore.org,"2025-08-21 15:28:40","Ages 20-64"
541,ve_child_vax_n,emeyerowit.montefiore.org,"2025-08-21 15:22:12","Ages 1-19"
541,ve_child_vax_n_2,emeyerowit.montefiore.org,"2025-08-21 15:27:57","Ages 1-19"
541,ve_em_type,emeyerowit.montefiore.org,"2025-08-21 15:20:25","Specified in Table S5"
543,ae_outcome1_disagg,abersm.gmail.com,"2025-07-31 11:48:43","Not for BNT162b2 specifically"
543,ae_outcome1_disagg_v2,abersm.gmail.com,"2025-07-31 11:49:34","Not for mRNA1273 specifically"
543,ae_outcome1_otherinfo_yn,abersm.gmail.com,"2025-07-31 11:48:18","Not for BNT162b2 specifically"
543,ae_outcome1_otherinfo_yn_v2,abersm.gmail.com,"2025-07-31 11:49:30","Not for mRNA1273 specifically"
543,design,abersm.gmail.com,"2025-07-31 11:45:23","Title says cross-sectional but actually a retrospective cohort study"
543,population_disagg,abersm.gmail.com,"2025-07-31 11:47:23","Age not disaggregated by specific vaccine"
544,ve_adult_em,scottja.stanford.edu,"2025-08-26 00:16:05","For the 20-64 year old group"
544,ve_adult_unvax_n,scottja.stanford.edu,"2025-08-26 00:11:11","The study reports that of the 11679 test-negative cases in the 20-64 years group, 16% were vaccinated. This means that 84% were not vaccinated, which is approximately 9,810 individuals."
544,ve_adult_unvax_y,scottja.stanford.edu,"2025-08-26 00:15:31","For the 20-64 years age group, there were 11,679 test-negative cases. Of these, 16% were vaccinated. This calculates to approximately 1,869 individuals."
544,ve_adult_vax_n,scottja.stanford.edu,"2025-08-26 00:09:20","Of the 4,079 test-positive cases in the 20-64 years group, 8% were vaccinated. This =  approximately 326 individuals"
544,ve_child_em,scottja.stanford.edu,"2025-08-25 02:23:31","The article provides separate adjusted VE estimates for two subgroups within this age range:


74% for the 6 months-9 years age group.
62% for the 10-19 years age group."
544,ve_child_em_adj,scottja.stanford.edu,"2025-08-25 02:24:04","74% for the 6 months-9 years age group.
62% for the 10-19 years age group"
544,ve_child_em_ci,scottja.stanford.edu,"2025-08-25 02:24:48","For the  6 months-9 years group, the 95% CI is 66-79.
For the 10-19 years group, the 95% CI is 32-78"
544,ve_child_unvax_n,scottja.stanford.edu,"2025-08-25 02:22:19","6 months-9 years: The total number of individuals who tested negative for influenza was 3,032. Of these, 15% were vaccinated, which means 85% were unvaccinated. That equals approximately 2,577 unvaccinated individuals who tested negative.
10-19 years: The total number of individuals who tested negative was 1,134. Of these, 7% were vaccinated, which means 93% were unvaccinated. That equals approximately 1,055 unvaccinated individuals who tested negative."
544,ve_child_unvax_n,scottja.stanford.edu,"2025-08-26 00:02:31","This number is a sum of the unvaccinated, test-negative individuals from the two subgroups: 2,577 (6 months-9 years) + 1,055 (10-19 years)"
544,ve_child_unvax_y,scottja.stanford.edu,"2025-08-26 00:02:53","This number is a sum of the vaccinated, test-negative individuals from the two subgroups: 455 (6 months-9 years) + 79 (10-19 years)."
544,ve_child_vax_n,scottja.stanford.edu,"2025-08-25 02:20:13","The study does not provide a single, combined number for this entire age range, but provides disaggregated data for two subgroups: 6 months-9 years and 10-19 years."
544,ve_child_vax_y,scottja.stanford.edu,"2025-08-26 00:02:08","This number is a sum of the vaccinated, test-positive individuals from the two subgroups: 92 (6 months-9 years) + 14 (10-19 years)."
544,ve_elder_unvax_y,scottja.stanford.edu,"2025-08-26 00:17:35","Of the 13,350 test-negative individuals, 43% were vaccinated, which is roughly 5,741 individuals."
544,ve_elder_vax_y,scottja.stanford.edu,"2025-08-26 00:16:58","Of the 1,952 test-positive cases, 30% were vaccinated, which is approximately 586 individuals."
544,ve_ic_unvax_y,scottja.stanford.edu,"2025-08-26 00:20:08","For the influenza A(H1N1) strain, 74% of the test-negative individuals in the comorbidity group were vaccinated, which = 15,953 individuals."
544,ve_ic_vax_y,scottja.stanford.edu,"2025-08-26 00:19:13","For the influenza A(H1N1 strain, 58% of the test-positive cases in the comorbidity group were vaccinated, which is approximately 2,822 individuals."
549,ve_adult_vax_n,flemi644,"2025-08-25 10:59:05","18-59 y"
549,ve_child_vax_n,flemi644,"2025-08-25 10:57:45","6-17 years"
549,ve_elder_vax_n,flemi644,"2025-08-25 11:00:05","60 + years"
549,ve_infant_vax_n,flemi644,"2025-08-25 10:54:10","Children 0-5 years"
549,ve_vax_type,flemi644,"2025-08-25 10:52:36","influenza vaccinations in Beijing during the 2024/25 season 
are inactivated influenza vaccines, with 87.1% being trivalent and 12.9% quadrivalent."
550,ae_outcome_4,flemi644,"2025-08-25 11:44:39","Hemorrhagic stroke"
550,ae_outcome_5,flemi644,"2025-08-25 11:46:46","Ischemic Stroke"
550,ae_outcome1_unvax_n,flemi644,"2025-08-25 11:39:44","control period"
550,design,flemi644,"2025-08-25 11:10:07","Observational, self-controlled risk interval study comparing AESI incidence in a pre-specified risk window after vaccination vs a control window after a 30-day washout"
551,population,abersm.gmail.com,"2025-07-30 14:52:17","Actual age criteria: age >= 60"
551,population_disagg,abersm.gmail.com,"2025-07-30 15:23:20","Data re disaggregated by 60-74, 75+"
551,ve_em_type,abersm.gmail.com,"2025-07-30 14:55:52","(1 - adjusted OR)*100"
551,ve_outcome_prime,abersm.gmail.com,"2025-07-30 15:00:17","RSV-associated hospitalization"
551,ve_overall_em,abersm.gmail.com,"2025-07-30 15:22:01","Unweighted (not inverse probability weighted)"
551,ve_overall_em_adj,abersm.gmail.com,"2025-07-30 15:22:14","Unweighted (not inverse probability weighted)"
551,ve_overall_em_ci,abersm.gmail.com,"2025-07-30 15:22:18","Unweighted (not inverse probability weighted)"
552,epi_ifr_rsv,stodd046,"2025-08-06 15:20:51","Authors group death with invasive mechanical ventilation"
553,epi_hospitalization_covid,flemi644,"2025-08-25 12:10:48","Vaccination = any U.S. licensed MRNA vaccine. Others excluded."
553,epi_medical_covid,flemi644,"2025-08-25 12:10:53","Vaccination = any U.S. licensed MRNA vaccine. Others excluded."
554,ae_outcome_v2,abersm.gmail.com,"2025-07-30 15:58:44","Adverse events were defined as ""myocarditis"" and  ""pericarditis ""using preferred terms in MedDRA. We defined vaccine-induced myocarditis/pericarditis as adverse event reports within the  ""narrow""  range. Furthermore, if  myocarditis/pericarditis was not described in the adverse event report, we defined the
adverse event as out of scope such as myocarditis/pericarditis."
554,ae_outcome1_longterm_yn,abersm.gmail.com,"2025-07-30 15:41:06","Death reported"
554,ae_outcome1_longterm_yn_v2,abersm.gmail.com,"2025-07-30 15:57:22",Death
554,ae_outcome1_otherinfo_yn,abersm.gmail.com,"2025-07-30 15:41:39","Time to onset following vaccination, sex"
554,ae_outcome1_otherinfo_yn_v2,abersm.gmail.com,"2025-07-30 15:57:36","Time to onset after vaccination, sex"
555,ae_outcome1_longterm_yn,abersm.gmail.com,"2025-07-30 16:08:39","Death, imaging abnormalities (cardiac MRI), persistent symptoms"
555,ae_outcome1_longterm_yn_v2,abersm.gmail.com,"2025-07-30 16:09:14","Death, imaging abnormalities (cardiac MRI), persistent symptoms"
555,design,abersm.gmail.com,"2025-07-30 16:06:13","Retrospective cohort"
556,ae_outcome1_em_value,stodd046,"2025-08-07 15:16:28","Authors merely say that acute MI was observed in 0.1% of vaccinated group, 0% of placebo group"
557,ae_outcome1_unvax_y,flemi644,"2025-08-25 12:43:14","38126 stroke events total - 1309 that occurred within 30 days of vaccination."
557,ae_outcome1_unvax_y,scottja.stanford.edu,"2025-08-26 00:41:21","The total number of stroke events was 38,126. Subtracting the 1,309 stroke events that occurred within 30 days of vaccination gives 38,126 - 1,309 = 36,817"
557,ae_outcome1_vax_n,flemi644,"2025-08-25 12:40:18","ever vaccinated during study window"
557,ae_outcome1_vax_y,flemi644,"2025-08-25 12:40:54","within 30 days of vaccination"
557,ae_outcome1_vax_y,flemi644,"2025-08-25 12:48:01","Table 1 lists ""Within 30 days: 16,004 events"" alongside HR 0.66 (0.65-0.68) with the footnote ""time windows are not mutually exclusive."" Given earlier text (1,309 strokes within 30 days of vaccination) and the step-up pattern 284→601→905→1286, ""16,004"" is likely an error. Abstract and text both list as 1309."
560,population,flemi644,"2025-08-12 12:55:47","All adults 18+ with cute respiratory infection "
560,ve_overall_em_adj,flemi644,"2025-08-12 13:19:31","Overall VE not reported"
560,ve_overall_vax_y_2,flemi644,"2025-08-12 13:14:42","from Figure s1"
565,design,abersm.gmail.com,"2025-07-31 10:11:30","Data provided to calculate incidence of events but study is primarily a case series"
567,design,moat0011,"2025-08-25 09:05:31","Used a cross-sectional design to obtain incidence info, later paired case/controls."
567,domain_ae_include_vax,moat0011,"2025-08-25 09:01:57","CoronaVac, AZD1222, or BNT162b2 COVID-19 vaccines"
567,population_disagg,moat0011,"2025-08-25 09:06:01","Only age < 60"
569,ve_vax_type,flemi644,"2025-08-25 15:00:10","Commercial QIV, Not U.S. Licensed, but comparable (Shenzhen Sanofi Pasteur Biological Products Co., Ltd.)"
570,ae_outcome1_vax_n,ejholmes,"2025-08-25 14:55:01","Dose 2, Pfizer"
570,ae_outcome1_vax_n_2,ejholmes,"2025-08-25 14:59:08","Dose 2"
570,domain_ae_include_vax,ejholmes,"2025-08-25 14:38:23","AZD, Pfizer, Moderna"
572,population_disagg,abersm.gmail.com,"2025-07-31 10:16:46","Individual patient data provided"
574,ae_outcome1_disagg,abersm.gmail.com,"2025-07-31 10:48:19","But raw data are publicly available."
574,ae_outcome1_disagg_2,abersm.gmail.com,"2025-07-31 10:49:23","But raw data are publicly available."
574,ae_outcome1_longterm_yn_2,abersm.gmail.com,"2025-07-31 10:49:37","But raw data are publicly available."
574,ae_outcome1_otherinfo_yn_2,abersm.gmail.com,"2025-07-31 10:49:32","But raw data are publicly available."
574,date_end_year,abersm.gmail.com,"2025-07-31 10:37:18","Methods section states 10/2022 was cutoff. Figure 1 shows data up to 10/2021 but only includes 69 of 86 total cases"
580,domain,flemi644,"2025-08-26 12:58:26","VE is out of range"
580,ve_outcome_two,scottja.stanford.edu,"2025-08-26 01:16:03","VE vs severe COVID-19, which was defined as ""an ICU admission or use of ventilatory support"
580,ve_overall_em_adj_2,scottja.stanford.edu,"2025-08-26 01:19:00","2-dose comparison"
580,ve_overall_em_adj_3,scottja.stanford.edu,"2025-08-26 01:24:02","3-dose comparison HR was 0.457."
580,ve_overall_em_ci_3,scottja.stanford.edu,"2025-08-26 01:24:23","3-dose comparison CI was 0.372-0.561"
581,design,abersm.gmail.com,"2025-07-31 10:56:57","Study also includes a cross-sectional analysis of survey data but less useful than VAERS data"
581,population_disagg,abersm.gmail.com,"2025-07-31 10:58:14","Not disaggregated by specific vaccine"
583,ve_adult_em_adj_2,emeyerowit.montefiore.org,"2025-08-27 19:36:19","Supplementary Table 1"
583,ve_adult_em_ci,emeyerowit.montefiore.org,"2025-08-27 19:34:36","SI Table 1 (Supplementary)"
583,ve_adult_vax_n,emeyerowit.montefiore.org,"2025-08-27 19:34:00","< 60"
583,ve_adult_vax_n_2,emeyerowit.montefiore.org,"2025-08-27 19:36:01","< 60"
583,ve_elder_vax_n,emeyerowit.montefiore.org,"2025-08-27 19:34:43",">60 years"
583,ve_elder_vax_n_2,emeyerowit.montefiore.org,"2025-08-27 19:36:23",>60
583,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-08-27 19:35:25","Table 2"
583,ve_overall_em_adj_2,emeyerowit.montefiore.org,"2025-08-27 19:37:02","Table 2"
584,domain_ae_include_vax,ejholmes,"2025-08-25 13:39:20","BNT162b2, mRNA-1273, ChAdOx1, and
Ad26.COV2.S,"
585,domain,moat0011,"2025-08-25 15:15:39","This article presents data for 3 different studies- results are separated by study"
585,population,moat0011,"2025-08-25 15:16:06","2-17y, 18-64y, 65+y"
585,ve_child_vax_n,moat0011,"2025-08-25 15:35:13",2y-17y
585,ve_child_vax_n_v2,moat0011,"2025-08-25 16:10:30",2y-17y
585,ve_child_vax_n_v2_v3,moat0011,"2025-08-25 16:20:57",2y-17y
585,ve_vax_type,moat0011,"2025-08-25 15:34:40","GB-PC Study Results"
585,ve_vax_type_v2,moat0011,"2025-08-25 15:39:17","Results for EN-H study"
585,ve_vax_type_v2_v3,moat0011,"2025-08-25 16:19:52","Results from SC-H study"
586,ae_outcome1_unvax_n,sundaram.maria.marshfieldresearch.org,"2025-08-06 13:45:09","Number of people vaccinated *separately* (i.e., not coadministered, but received 2 vaccines 28 days apart)"
586,ae_outcome1_vax_n,sundaram.maria.marshfieldresearch.org,"2025-08-06 13:44:34","Number of people in *coadministration* group"
589,ae_outcome1_em_ci,ulric063,"2025-08-25 17:44:00","Not estimable"
589,ae_outcome1_em_value,ulric063,"2025-08-25 17:43:46","Not estimable"
589,ae_outcome1_unvax_n,ulric063,"2025-08-25 17:42:45","Number with sequential vaccination"
589,ae_outcome1_vax_n,ulric063,"2025-08-25 17:42:32","Number with concomitant vaccination with PPSV-23"
589,coadmin_ae_describe,ulric063,"2025-08-25 17:33:51","Adjusted IRR compared to sequential administration"
590,population,abersm.gmail.com,"2025-08-02 10:55:45","Age criteria (for study inclusion) not mentioned. Age range of patients in study 2-41 years"
591,domain_ae_include_vax,abersm.gmail.com,"2025-08-02 10:48:34","Ad26.COV2.S and NVX-CoV2373 also included in study but no IRR calculated for these vaccines (0 PMR cases for these vaccines. Total number who received these vaccines not mentioned)."
591,population,abersm.gmail.com,"2025-08-02 10:50:13","Age >= 50"
591,population_disagg,abersm.gmail.com,"2025-08-02 10:50:54","Age not disaggregated by vaccine type."
601,immunocomp_describe,stodd046,"2025-08-22 14:14:24",""" These underlying
medical conditions included diabetes, hypertension, heart disease, chronic
pulmonary conditions, weakened immune system, cancer, kidney failure,
and a body mass index (BMI) >30"""
605,date_end_year,abersm.gmail.com,"2025-07-31 11:03:14","This is the end date for Bell's palsy diagnosis. End date for vaccination is 3/1/2022"
607,design,abersm.gmail.com,"2025-07-31 11:14:42",Survey
610,ae_outcome1_otherinfo_yn,abersm.gmail.com,"2025-08-02 11:12:48","Age, sex, time to onset (after vaccination), whether MRI/echo abnormal, whether troponin elevated"
610,ae_outcome1_otherinfo_yn_v2,abersm.gmail.com,"2025-08-02 11:16:32","Age, sex, time to onset (after vaccination), whether MRI/echo abnormal, whether troponin elevated"
610,design,abersm.gmail.com,"2025-08-02 11:09:06","Retrospective study of myopericarditis, myocarditis, and pericarditis"
610,population_disagg,abersm.gmail.com,"2025-08-02 11:11:26","Individual patient data provided"
614,population_disagg,abersm.gmail.com,"2025-07-31 11:22:49","Not disaggregated by specific vaccine"
615,population,moat0011,"2025-08-25 13:28:31","0-5y
6-18y
19-59y
>=60y"
615,ve_adult_vax_n,moat0011,"2025-08-25 14:02:01",19y-59y
615,ve_child_vax_n,moat0011,"2025-08-25 13:44:20",6y-18y
615,ve_elder_vax_n,moat0011,"2025-08-25 14:03:13",>=60y
615,ve_infant_vax_n,moat0011,"2025-08-25 13:40:12",0-5y
616,coadmin_vax_prime,flemi644,"2025-08-25 15:34:22","Non U.S. licensed, but comparable"
616,population,flemi644,"2025-08-25 15:33:25","Adults 60+"
617,ve_adult_em,ulric063,"2025-08-25 16:33:09","stratified into 2 age groups: 
18-49: 39 (36-41)
50-64: 27 (23-30)"
617,ve_adult_em_adj,ulric063,"2025-08-25 16:33:13","stratified into 2 age groups:
18-49: 36
50-64: 30"
617,ve_adult_em_ci,ulric063,"2025-08-25 16:33:17","stratified into 2 age groups:
18-49: 46-50
50-64: 33-39"
617,ve_adult_unvax_n,ulric063,"2025-08-25 16:33:00","stratified into 2 age groups: 
18-49: 189129
50-64: 96148"
617,ve_adult_unvax_y,ulric063,"2025-08-25 16:33:04","stratified into 2 age groups: 
18-49: 36171
50-64: 28579"
617,ve_adult_vax_n,ulric063,"2025-08-25 16:31:42","stratified into 2 age groups: 
18-49: 26435
50-64: 10861"
617,ve_adult_vax_y,ulric063,"2025-08-25 16:31:48","stratified into 2 age groups: 
18-49: 3334
50-64: 2575"
618,ve_adult_em,moat0011,"2025-08-25 17:19:41","VE 18-49y: 42 (41-44)
VE 50-64y: 30(27-32)"
618,ve_adult_vax_n,moat0011,"2025-08-25 17:17:22","Combined the 18-49 and 50-64 subgroups here"
619,ve_child_em,ejholmes,"2025-08-25 16:28:18","For 2023-24 season; Flu A&B"
619,ve_child_vax_n,moat0011,"2025-08-25 14:56:21","3-9y; VE= 41% (95% CI: 34-47)
9-< 18; VE= 23% (-3-43)"
619,ve_infant_vax_n,moat0011,"2025-08-25 14:54:01","0.5-< 3y"
619,ve_overall_em,ejholmes,"2025-08-25 16:29:50","Across all flu seasons (2021-2024); Flu A&B"
621,ve_comparator1,scottja.stanford.edu,"2025-08-26 01:55:30","The study compared those who received an updated dose to a group of patients who did not receive an updated dose. This group included both patients who had received previous COVID-19 vaccine doses and those who had never received a dose."
621,ve_outcome_num,scottja.stanford.edu,"2025-08-26 02:07:10","The study evaluated a composite outcome of invasive mechanical ventilation or death. However, the results presented for this outcome are adjusted odds ratios comparing the JN lineage to the XBB lineage, not a direct VE against an unvaccinated group."
621,ve_overall_em_adj,scottja.stanford.edu,"2025-08-26 02:02:09","The study also provides data for the JN lineage. The adjusted VE against JN lineage hospitalization was 32.7% (95% CI, 1.9-53.8%). The number of vaccinated cases was 38, and the number of vaccinated controls was 844."
621,ve_overall_vax_n,scottja.stanford.edu,"2025-08-26 02:01:00","XBB lineage"
627,ve_child_vax_n,emeyerowit.montefiore.org,"2025-08-11 21:09:38","Total ""catch up"" cohort, including premies"
627,ve_infant_vax_n,emeyerowit.montefiore.org,"2025-08-11 21:09:20","""total ""born during season"" cohort"" including premies"
628,population,moat0011,"2025-08-25 13:12:35",">=80 years"
628,ve_elder_vax_n_2,arpey001,"2025-08-26 10:59:59","Only full vaccine, not partial"
628,ve_elder_vax_y_2,arpey001,"2025-08-26 11:05:57","Only full vaccine group"
629,ve_overall_em,ncmccann.bu.edu,"2025-08-11 22:00:37",adjusted
629,ve_overall_em_2,ncmccann.bu.edu,"2025-08-11 22:02:22",adjusted
629,ve_timeline,scottja.stanford.edu,"2025-08-11 23:52:33","""Eligible infants could therefore be aged between0 and 5 months."" ""This study evaluating the effectiveness of RSVpreF
maternal vaccination within the first 5 months of
national implementation indicated that vaccination was
effective against RSV-associated ALRI leading to hospitalisation. """
630,epi_hospitalization_rsv,ncmccann.bu.edu,"2025-08-12 10:55:51","hospitalizations / infections; summed table 1 numbers to get overall %"
630,epi_hospitalization_rsv,flemi644,"2025-08-12 11:24:54","added per 100K rates"
630,epi_ifr_rsv,ncmccann.bu.edu,"2025-08-12 10:58:27","in-hospital mortality / total infections (would miss mortality outside of hospital)"
630,epi_ifr_rsv,flemi644,"2025-08-12 11:25:07","added per 100k rates"
630,epi_sample_rsv,ncmccann.bu.edu,"2025-08-12 10:53:37","1660 total identified with infections (CD+ALF+SNF); incidence rates are calculated from broader population data"
631,ve_adult_em,ncmccann.bu.edu,"2025-08-11 22:28:44",adjusted
631,ve_overall_unvax_n_3,scottja.stanford.edu,"2025-08-12 00:28:57","2,506 pregnant + 43,671 non-pregnant"
631,ve_overall_unvax_y_3,scottja.stanford.edu,"2025-08-12 00:29:06","862 pregnant + 11,769 non-pregnant"
631,ve_overall_vax_n_3,scottja.stanford.edu,"2025-08-12 00:28:20","1,033 pregnant + 14,038 non-pregnant"
631,ve_overall_vax_y_3,scottja.stanford.edu,"2025-08-12 00:28:35","249 pregnant + 2,114 non-pregnant"
631,ve_overall_yn_3,ncmccann.bu.edu,"2025-08-11 22:34:46","Added this under its own outcome for combined urgent care and ED visits b/c the overall population estimate for non preg + preg women is not stratified by visit type"
633,ae_incidence_yn,stodd046,"2025-08-25 11:42:29","Events/person days = 34/14930"
633,ae_incidence_yn_2,stodd046,"2025-08-25 11:42:51","Events/person days = 71/40130"
633,ae_incidence_yn_2_v2,stodd046,"2025-08-25 11:48:42","Events/person days = 51/26093"
633,ae_incidence_yn_3,stodd046,"2025-08-25 11:43:20","Events/person days = < 20/7897"
633,ae_incidence_yn_3_v2,stodd046,"2025-08-25 11:49:56","Events/person days = 0/784"
633,ae_incidence_yn_4,stodd046,"2025-08-25 11:46:35","Events/person days = < 20/3047"
633,ae_incidence_yn_4_v2,stodd046,"2025-08-25 11:51:48","Events/person days = < 20/1475"
633,ae_incidence_yn_v2,stodd046,"2025-08-25 11:48:02","Events/person days = < 20/7897"
633,ae_outcome_4,stodd046,"2025-08-25 11:44:47",Myo/pericarditis
633,date_start_month,stodd046,"2025-08-25 11:39:44","study start date, patient selection occurred 9/23-6/24"
635,virus,scottja.stanford.edu,"2025-08-14 23:12:03","The covid vaccine data wasn't disaggregated and the highest signal was for flu vaccines, which I entered as a comment."
636,exclude,scottja.stanford.edu,"2025-08-12 00:49:02","This meets our protocol criteria, in my opinion."
636,exclude,emeyerowit.montefiore.org,"2025-08-12 06:35:07",Agree
638,date_end_month,flemi644,"2025-08-15 17:34:28","Date cutoff October 2024 (methods->assessments)"
638,domain_ae_include_list,flemi644,"2025-08-15 17:35:47","Myocarditis/pericarditis was monitored as an AESI; none reported"
639,domain_ae_include_yn,ulric063,"2025-08-20 13:19:49","19 participants excluded for severe adverse events leading to hospitalization within 7 days of vaccination. Not disaggregated by vaccine type. (respiratory distress (n=4), kidney failure (n=2), chest pain & cardiac problem (n=7), severe anaphylactic shock (n=5))."
639,population,ulric063,"2025-08-20 13:10:26","Adults over the age of 18; unclear if/how many participants were >65"
640,coadmin_ae_describe,ulric063,"2025-08-20 14:23:42","Authors report: Data mining detected no new safety signals, and comparative analysis revealed that co-administration safety aligned with clinical trial profiles and monotherapy (influenza/
RZV alone), showing no elevated risks."
640,coadmin_ae_yn,ulric063,"2025-08-20 14:34:45","No statistical test of the association, so selecting ""yes"" here to provide detailed count data aon each outcome below. Authors report: Data mining detected no new safety signals, and comparative analysis revealed that co-administration safety aligned with clinical trial profiles and monotherapy (influenza/
RZV alone), showing no elevated risks."
640,coadmin_outcome_other,ulric063,"2025-08-20 14:26:57","Authors report: Data mining detected no new safety signals, and comparative analysis revealed that co-administration safety aligned with clinical trial profiles and monotherapy (influenza/
RZV alone), showing no elevated risks."
640,design,ulric063,"2025-08-20 13:58:26","Data mining using VAERS reports"
641,ae_outcome,ulric063,"2025-08-21 17:37:20","Pericarditis was presented as a separate outcome:
8 events /77,417 PY with JN1
338 events /1,310,773 PY without JN1
IRR: 0.42 (0.20-0.89)"
641,ae_outcome1_unvax_n_2,ulric063,"2025-08-21 17:39:10","denominator is person-years"
641,ae_outcome1_unvax_n_3,ulric063,"2025-08-21 17:41:34","denominator is person-years"
641,ae_outcome1_vax_n,ulric063,"2025-08-21 17:32:57","Denominator is 77,489 person-years"
641,ae_outcome1_vax_n_2,ulric063,"2025-08-21 17:38:45","denominator is person-years"
641,ae_outcome1_vax_n_3,ulric063,"2025-08-21 17:40:58","denominator is person-years"
641,ae_vax_type,ulric063,"2025-08-21 17:51:24","JN.1-containing vaccines"
641,domain_ae_num,ulric063,"2025-08-21 17:08:10","Vaccinated with a primary course and one booster Covid-19 vaccine, defined as registered three previous Covid-19 vaccines received with the BNT162b2 and/or mRNA-1273 as well
as and/or AZD1222 vaccine (the latter as part of the primary vaccination course only). Other vaccine types were rare within our source population and were treated as censoring events."
642,ae_incidence_yn_v2,ejholmes,"2025-08-25 14:25:22","0 CVST cases found with mRNA COVID vaccination"
642,ae_incidence_yn_v3,ejholmes,"2025-08-25 14:26:05","0 CVST cases found with mRNA COVID vaccination"
642,ae_outcome,ejholmes,"2025-08-25 14:24:11","0 CVST cases found with J&J vaccination"
643,coadmin_vax2_type,emeyerowit.montefiore.org,"2025-08-14 12:21:41","COVID vaccines not disaggregated. Only Moderna and Pfizer allowed"
